AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
NeutropeniaFebrile NeutropeniaChemotherapy-Induced Febrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsFeverTaxoidsChemotherapy, AdjuvantDrug Administration ScheduleGranulocyte Colony-Stimulating FactorTreatment OutcomeCisplatinAntineoplastic AgentsPaclitaxelDoxorubicinNeoplasmsCyclophosphamideInfusions, IntravenousDeoxycytidineVinblastineDisease-Free SurvivalSurvival AnalysisCombined Modality TherapyAntineoplastic Agents, PhytogenicCamptothecinLung NeoplasmsCarboplatinAgranulocytosisBreast NeoplasmsMaximum Tolerated DoseSurvival RateEtoposideNeoplasm StagingFever of Unknown OriginOrganoplatinum CompoundsIfosfamideMycosesThrombocytopeniaHematologic DiseasesNeoadjuvant TherapyHematologic NeoplasmsDose-Response Relationship, DrugNeoplasm MetastasisLeukopeniaFluorouracilCarcinoma, Non-Small-Cell LungNauseaAnthracyclinesEpirubicinAntimetabolites, AntineoplasticBacterial InfectionsSalvage TherapyProspective StudiesNeoplasm Recurrence, LocalPrognosisLymphoma, Non-HodgkinAnti-Bacterial AgentsMethotrexateOpportunistic InfectionsDrug Resistance, NeoplasmMucositisAntibiotic ProphylaxisImmunocompromised HostVomitingOxonic AcidTegafurAdenocarcinomaPenicillanic AcidMitoxantroneLeucovorinTime FactorsAdministration, OralDisease ProgressionLeukocyte CountAntineoplastic Agents, AlkylatingOvarian NeoplasmsFollow-Up StudiesBleomycinPlatinum CompoundsDrug-Related Side Effects and Adverse ReactionsAntibiotics, AntineoplasticFeasibility StudiesBacteremiaKaplan-Meier EstimateTopotecanBridged CompoundsRecombinant ProteinsGuanineAlopeciaAntibodies, Monoclonal, HumanizedVincristineStomach NeoplasmsPiperacillinColorectal NeoplasmsAntifungal AgentsAmikacinStomatitisInfectionInduction ChemotherapyAntibodies, Monoclonal, Murine-DerivedRecurrenceGlutamatesTransplantation, AutologousUrologic NeoplasmsPeritoneal NeoplasmsRetrospective StudiesHematologyPrednisoneLeukemia, Myeloid, AcuteRandomized Controlled Trials as TopicClinical Trials as TopicBiosimilar PharmaceuticalsHematopoietic Stem Cell TransplantationAmbulatory CareCarcinoma, Small CellPrecursor Cell Lymphoblastic Leukemia-LymphomaComplement Hemolytic Activity AssayRisk FactorsArea Under CurveAntibodies, MonoclonalCancer Care FacilitiesThienamycinsCytarabineLymphomaSarcomaDrug Therapy, CombinationCarcinoma, Squamous CellRemission InductionGram-Negative Bacterial InfectionsAmphotericin BQuality of LifeTreatment FailurePrednisoloneAnemiaCarcinomaPilot ProjectsDacarbazineLength of StayLymphatic MetastasisCarcinoma, Transitional CellHead and Neck NeoplasmsRisk AssessmentNeutrophilsCephalosporinsDrug CombinationsColony-Stimulating FactorsGram-Positive Bacterial InfectionsDiarrheaCeftazidimeChemotherapy, Cancer, Regional PerfusionRadiotherapy, AdjuvantHodgkin DiseaseFelty SyndromeLeukocyte ElastaseArabinonucleosidesInjections, IntravenousFatigueMultivariate AnalysisBrain NeoplasmsRadiotherapyMelphalanBone MarrowDouble-Blind MethodTesticular NeoplasmsCarmustineInappropriate PrescribingMitomycinBone NeoplasmsLiver NeoplasmsReceptor, erbB-2Esophageal NeoplasmsGranulocyte-Macrophage Colony-Stimulating FactorBlood Cell CountLomustineAnti-Infective AgentsHealth Care CostsReceptors, Granulocyte Colony-Stimulating FactorHospitalizationInfusions, Intra-ArterialPredictive Value of TestsCohort StudiesPalliative CareDrug EvaluationRadiotherapy DosageCost-Benefit AnalysisNeoplasms, Germ Cell and EmbryonalThiotepaCalcitoninDrug TherapyDaunorubicinEchinocandinsTumor Markers, BiologicalMannose-Binding LectinJapanVindesineOsteosarcomaBone Marrow DiseasesAntiemeticsBone Marrow TransplantationAge FactorsPlatinumLeukemia, Myeloid
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.Chemotherapy-Induced Febrile Neutropenia: FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.Taxoids: A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Granulocyte Colony-Stimulating Factor: A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Paclitaxel: A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.DeoxycytidineVinblastine: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Antineoplastic Agents, Phytogenic: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.Lung Neoplasms: Tumors or cancer of the LUNG.Carboplatin: An organoplatinum compound that possesses antineoplastic activity.Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).Breast Neoplasms: Tumors or cancer of the human BREAST.Maximum Tolerated Dose: The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Fever of Unknown Origin: Fever in which the etiology cannot be ascertained.Organoplatinum Compounds: Organic compounds which contain platinum as an integral part of the molecule.Ifosfamide: Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.MycosesThrombocytopenia: A subnormal level of BLOOD PLATELETS.Hematologic Diseases: Disorders of the blood and blood forming tissues.Neoadjuvant Therapy: Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.LeukopeniaFluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.Anthracyclines: Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Bacterial Infections: Infections by bacteria, general or unspecified.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Anti-Bacterial Agents: Substances that reduce the growth or reproduction of BACTERIA.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).Antibiotic Prophylaxis: Use of antibiotics before, during, or after a diagnostic, therapeutic, or surgical procedure to prevent infectious complications.Immunocompromised Host: A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.Oxonic Acid: Antagonist of urate oxidase.Tegafur: Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed)Mitoxantrone: An anthracenedione-derived antineoplastic agent.Leucovorin: The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Leukocyte Count: The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.Antineoplastic Agents, Alkylating: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Bleomycin: A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.Platinum Compounds: Inorganic compounds which contain platinum as the central atom.Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Feasibility Studies: Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.Bridged Compounds: Cyclic hydrocarbons that contain multiple rings and share one or more atoms.Recombinant Proteins: Proteins prepared by recombinant DNA technology.GuanineAlopecia: Absence of hair from areas where it is normally present.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Stomach Neoplasms: Tumors or cancer of the STOMACH.Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Antifungal Agents: Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.Infection: Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.Induction Chemotherapy: Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Recurrence: The return of a sign, symptom, or disease after a remission.Glutamates: Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Urologic Neoplasms: Tumors or cancer of the URINARY TRACT in either the male or the female.Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Hematology: A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Randomized Controlled Trials as Topic: Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Biosimilar Pharmaceuticals: BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Ambulatory Care: Health care services provided to patients on an ambulatory basis, rather than by admission to a hospital or other health care facility. The services may be a part of a hospital, augmenting its inpatient services, or may be provided at a free-standing facility.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.Complement Hemolytic Activity Assay: A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Area Under Curve: A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Cancer Care Facilities: Institutions specializing in the care of cancer patients.Thienamycins: Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Gram-Negative Bacterial Infections: Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.Quality of Life: A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.Treatment Failure: A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Pilot Projects: Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.Dacarbazine: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)Length of Stay: The period of confinement of a patient to a hospital or other health facility.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)Neutrophils: Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.Cephalosporins: A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.Drug Combinations: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.Colony-Stimulating Factors: Glycoproteins found in a subfraction of normal mammalian plasma and urine. They stimulate the proliferation of bone marrow cells in agar cultures and the formation of colonies of granulocytes and/or macrophages. The factors include INTERLEUKIN-3; (IL-3); GRANULOCYTE COLONY-STIMULATING FACTOR; (G-CSF); MACROPHAGE COLONY-STIMULATING FACTOR; (M-CSF); and GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; (GM-CSF).Gram-Positive Bacterial Infections: Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.Ceftazidime: Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.Chemotherapy, Cancer, Regional Perfusion: Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Felty Syndrome: A rare complication of rheumatoid arthritis with autoimmune NEUTROPENIA; and SPLENOMEGALY.Leukocyte Elastase: An enzyme that catalyzes the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of Ala and Val, with greater specificity for Ala. EC 3.4.21.37.Arabinonucleosides: Nucleosides containing arabinose as their sugar moiety.Injections, Intravenous: Injections made into a vein for therapeutic or experimental purposes.Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)Inappropriate Prescribing: The practice of administering medications in a manner that poses more risk than benefit, particularly where safer alternatives exist.Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Liver Neoplasms: Tumors or cancer of the LIVER.Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Granulocyte-Macrophage Colony-Stimulating Factor: An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.Blood Cell Count: The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.Lomustine: An alkylating agent of value against both hematologic malignancies and solid tumors.Anti-Infective Agents: Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.Health Care Costs: The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost.Receptors, Granulocyte Colony-Stimulating Factor: Receptors that bind and internalize GRANULOCYTE COLONY-STIMULATING FACTOR. Their MW is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells.Hospitalization: The confinement of a patient in a hospital.Infusions, Intra-Arterial: Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Palliative Care: Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)Drug Evaluation: Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Cost-Benefit Analysis: A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Calcitonin: A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.Drug Therapy: The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.Echinocandins: Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Mannose-Binding Lectin: A specific mannose-binding member of the collectin family of lectins. It binds to carbohydrate groups on invading pathogens and plays a key role in the MANNOSE-BINDING LECTIN COMPLEMENT PATHWAY.JapanVindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)Bone Marrow DiseasesAntiemetics: Drugs used to prevent NAUSEA or VOMITING.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.Platinum: Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.

Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. (1/10)

BACKGROUND: Febrile neutropenia (FN) is a serious complication following chemotherapy and is associated with significant mortality and financial expenditure. The aim of this study was to evaluate risk factors for longer length of stay (LOS) and mortality and cost of treatment among hospitalized adults with cancer who developed febrile neutropenia in Thailand. MATERIALS AND METHODS: Information on illness of inpatients and casualties came from hospitals nationwide and from hospital withdrawals from the 3 health insurance schemes in fiscal 2010. The data covered 96% of the population and were analyzed by age groups, hospital level, and insurance year schemes in patients with febrile neutropenia. RESULTS: A total of 5,809 patients were identified in the study. The mortality rate was 14%. The median LOS was 8.67 days and 69% of patients stayed for longer than 5 days. On bivariate analysis, age, cancer type, and infectious complications (bacteremia/sepsis, hypotension, fungal infections, and pneumonia) were significantly associated with longer LOS and death. On multivariate analysis, acute leukemia and infectious complications were linked with longer LOS and death significantly. The median cost of hospitalized FN was THB 33,686 (USD 1,122) with the highest cost observed in acute leukemia patients. CONCLUSIONS: FN in adult patients results in significant mortality in hospitalized Thai patients. Factors associated with increased mortality include older age (>70), acute leukemia, comorbidity, and infectious complications.  (+info)

Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. (2/10)

 (+info)

Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. (3/10)

 (+info)

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. (4/10)

 (+info)

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. (5/10)

 (+info)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. (6/10)

 (+info)

Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). (7/10)

 (+info)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. (8/10)

 (+info)

AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
NeutropeniaFebrile NeutropeniaChemotherapy-Induced Febrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsFeverTaxoidsChemotherapy, AdjuvantDrug Administration ScheduleGranulocyte Colony-Stimulating FactorTreatment OutcomeCisplatinAntineoplastic AgentsPaclitaxelDoxorubicinNeoplasmsCyclophosphamideInfusions, IntravenousDeoxycytidineVinblastineDisease-Free SurvivalSurvival AnalysisCombined Modality TherapyAntineoplastic Agents, PhytogenicCamptothecinLung NeoplasmsCarboplatinAgranulocytosisBreast NeoplasmsMaximum Tolerated DoseSurvival RateEtoposideNeoplasm StagingFever of Unknown OriginOrganoplatinum CompoundsIfosfamideMycosesThrombocytopeniaHematologic DiseasesNeoadjuvant TherapyHematologic NeoplasmsDose-Response Relationship, DrugNeoplasm MetastasisLeukopeniaFluorouracilCarcinoma, Non-Small-Cell LungNauseaAnthracyclinesEpirubicinAntimetabolites, AntineoplasticBacterial InfectionsSalvage TherapyProspective StudiesNeoplasm Recurrence, LocalPrognosisLymphoma, Non-HodgkinAnti-Bacterial AgentsMethotrexateOpportunistic InfectionsDrug Resistance, NeoplasmMucositisAntibiotic ProphylaxisImmunocompromised HostVomitingOxonic AcidTegafurAdenocarcinomaPenicillanic AcidMitoxantroneLeucovorinTime FactorsAdministration, OralDisease ProgressionLeukocyte CountAntineoplastic Agents, AlkylatingOvarian NeoplasmsFollow-Up StudiesBleomycinPlatinum CompoundsDrug-Related Side Effects and Adverse ReactionsAntibiotics, AntineoplasticFeasibility StudiesBacteremiaKaplan-Meier EstimateTopotecanBridged CompoundsRecombinant ProteinsGuanineAlopeciaAntibodies, Monoclonal, HumanizedVincristineStomach NeoplasmsPiperacillinColorectal NeoplasmsAntifungal AgentsAmikacinStomatitisInfectionInduction ChemotherapyAntibodies, Monoclonal, Murine-DerivedRecurrenceGlutamatesTransplantation, AutologousUrologic NeoplasmsPeritoneal NeoplasmsRetrospective StudiesHematologyPrednisoneLeukemia, Myeloid, AcuteRandomized Controlled Trials as TopicClinical Trials as TopicBiosimilar PharmaceuticalsHematopoietic Stem Cell TransplantationAmbulatory CareCarcinoma, Small CellPrecursor Cell Lymphoblastic Leukemia-LymphomaComplement Hemolytic Activity AssayRisk FactorsArea Under CurveAntibodies, MonoclonalCancer Care FacilitiesThienamycinsCytarabineLymphomaSarcomaDrug Therapy, CombinationCarcinoma, Squamous CellRemission InductionGram-Negative Bacterial InfectionsAmphotericin BQuality of LifeTreatment FailurePrednisoloneAnemiaCarcinomaPilot ProjectsDacarbazineLength of StayLymphatic MetastasisCarcinoma, Transitional CellHead and Neck NeoplasmsRisk AssessmentNeutrophilsCephalosporinsDrug CombinationsColony-Stimulating FactorsGram-Positive Bacterial InfectionsDiarrheaCeftazidimeChemotherapy, Cancer, Regional PerfusionRadiotherapy, AdjuvantHodgkin DiseaseFelty SyndromeLeukocyte ElastaseArabinonucleosidesInjections, IntravenousFatigueMultivariate AnalysisBrain NeoplasmsRadiotherapyMelphalanBone MarrowDouble-Blind MethodTesticular NeoplasmsCarmustineInappropriate PrescribingMitomycinBone NeoplasmsLiver NeoplasmsReceptor, erbB-2Esophageal NeoplasmsGranulocyte-Macrophage Colony-Stimulating FactorBlood Cell CountLomustineAnti-Infective AgentsHealth Care CostsReceptors, Granulocyte Colony-Stimulating FactorHospitalizationInfusions, Intra-ArterialPredictive Value of TestsCohort StudiesPalliative CareDrug EvaluationRadiotherapy DosageCost-Benefit AnalysisNeoplasms, Germ Cell and EmbryonalThiotepaCalcitoninDrug TherapyDaunorubicinEchinocandinsTumor Markers, BiologicalMannose-Binding LectinJapanVindesineOsteosarcomaBone Marrow DiseasesAntiemeticsBone Marrow TransplantationAge FactorsPlatinumLeukemia, Myeloid

*Monocytopenia

Oguz A, Karadeniz C, Ckitak EC, Cil V (2006). "Which one is a risk factor for chemotherapy-induced febrile neutropenia in ... "Early monocytopenia after chemotherapy as a risk factor for neutropenia". Am. J. Clin. Oncol. 22 (1): 103-5. doi:10.1097/ ... It has been proposed as a measure to predict neutropenia, though some research indicates that it is less effective than ...

*Máté Hidvégi

Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients. J Pediatric Hematol ... Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor ...

*Angiopoietin

... concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia". BMC ... This quiescence or slow cell cycling of HSCs induced by Tie-2/Ang-1 signaling contributes to the maintenance of long-term ... 2013). "Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells". J Virol. 87 ( ... Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells. Angiopoietin-2 is ...

*Docetaxel

Haematological adverse effects include neutropenia (95.5%), anaemia (90.4%), febrile neutropenia (11.0%) and thrombocytopenia ( ... As with all chemotherapy, adverse effects are common, and many side effects have been documented. Because docetaxel is a cell- ... When used with anticonvulsants, which induce CYP3A4, an increased dose of docetaxel may be required. Pre-treatment with ... It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein. Common side ...

*Meropenem

... is frequently given in the treatment of febrile neutropenia. This condition frequently occurs in patients with ... Margolin, L (2004). "Impaired rehabilitation secondary to muscle weakness induced by meropenem". Clinical drug investigation. ... Antimicrobial Agents and Chemotherapy. 54 (7): 2974-8. doi:10.1128/AAC.01582-09. PMC 2897321 . PMID 20479205. Mosby's Drug ... Journal of Antimicrobial Chemotherapy. doi:10.1093/jac/dkw476/2691388/peptide-conjugated-phosphorodiamidate-morpholino. ...

*Piperacillin/tazobactam

... and empirical therapy in febrile neutropenia (e.g., after chemotherapy). The drug is administered intravenously every 6 or 8 hr ... or antibiotic-induced thrombocytopenia". 85 (1): 71-74. doi:10.1002/ajh.21536. PMC 4410979 . PMID 19802882. "Drug Shortages › ...

*Fever

A neutropenic fever, also called febrile neutropenia, is a fever in the absence of normal immune system function. Because of ... it is sometimes difficult to determine a febrile stage. Fever can also be behaviorally induced by invertebrates that do not ... This kind of fever is more commonly seen in people receiving immune-suppressing chemotherapy than in apparently healthy people ... Febrile is from the Latin word febris, meaning fever, and archaically known as ague. Fever phobia is the name given by medical ...

*Anthracycline

Use of anthracyclines has also been shown to be significantly associated with cycle 1 severe or febrile neutropenia. Other ... Kremer L, van Dalen E, Offringa M, Ottenkamp J, Voûte P (2001). "Anthracycline-induced clinical heart failure in a cohort of ... Anthracyclines are a class of drugs used in cancer chemotherapy extracted from Streptomyces bacterium such as Streptomyces ... Kesler, S. R; Blayney, D. W (2016). "Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition ...

*List of cutaneous conditions

Chemotherapy-induced hyperpigmentation Drug-induced acne Drug-induced angioedema Drug-related gingival hyperplasia Drug-induced ... Cyclic neutropenia Desquamative gingivitis Drug-induced ulcer of the lip Epidermization of the lip Epulis Epulis fissuratum ( ... Acne aestivalis (Mallorca acne) Acne conglobata Acne cosmetica (cosmetic acne) Acne fulminans (acute febrile ulcerative acne) ... induced Hair dye-induced Hair lotion-induced Hair spray-induced Hair straightener-induced Hair tonic-induced Houseplant-induced ...

*Pixantrone

... and a significant reduction in febrile neutropenia. These findings could have major implications for treating patients with ... Anthracyclines are important chemotherapy agents. However, their use is associated with irreversible and cumulative heart ... Pixantrone inhibits antigen specific and mitogen induced lymphomononuclear cell proliferation, as well as IFN-gamma production ... randomized clinical trial studied pixantrone to see how well it works compared to other chemotherapy drugs in treating patients ...
Nivestim 12 MU/ 0.2 ml solution for injection/infusion, Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48MU/...  Nivestim 12 MU/ 0.2 ml solution for injection/infusion, Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48MU/...
Nivestim 12 MU/ 0.2 ml solution for injection/infusion, Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48MU/ 0.5 ml solution for injection/infusion - Summary of Product Characteristics (SmPC) by Hospira UK Ltd
https://www.medicines.org.uk/emc/product/575
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors<...  Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors<...
TY - JOUR. T1 - Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. AU - Lambertini, Matteo. AU - Ferreira, Arlindo R.. AU - Del Mastro, Lucia. AU - Danesi, Romano. AU - Pronzato, Paolo. PY - 2015/10/22. Y1 - 2015/10/22. N2 - Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects. Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile ...
https://moh-it.pure.elsevier.com/en/publications/pegfilgrastim-for-the-prevention-of-chemotherapy-induced-febrile-
MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL | MorphoSys AG  MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL | MorphoSys AG
June 02, 2017 / 7:30 am, CEST Planegg/Munich, Germany, June 2, 2017. MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL. First pivotal study with compound from MorphoSyss proprietary portfolio started, following IDMC recommendation after initial safety evaluation. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the pivotal phase 3 part of the B-MIND clinical study of MOR208 has been opened for enrollment. The randomized, multicenter phase 2/3 study is designed to investigate the efficacy of MOR208 plus bendamustine versus rituximab plus bendamustine in patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). DLBCL is the most common form of non-Hodgkins lymphoma. MOR208 is an investigational, Fc-enhanced monoclonal antibody directed against CD19 and is being developed for the ...
https://www.morphosys.com/media-investors/media-center/morphosys-starts-phase-3-trial-of-mor208-plus-bendamustine-in-patients
TORCH - University of Birmingham  TORCH - University of Birmingham
TORCH: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL).
https://www.birmingham.ac.uk/research/activity/mds/trials/crctu/trials/haematology/torch/index.aspx
Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]  Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]
RESULTS: Mean age of the patients was 57 years. Mean absolute neutrophil count (ANC) was 436.8/mm3 (range: 0-1000/mm3). In all, 23 of the patients (22.5%) died due to complications related to FN. There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy ...
http://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-27136&look4=
Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]  Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]
RESULTS: Mean age of the patients was 57 years. Mean absolute neutrophil count (ANC) was 436.8/mm3 (range: 0-1000/mm3). In all, 23 of the patients (22.5%) died due to complications related to FN. There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy ...
http://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-27136
Kaliuresis - Wikipedia  Kaliuresis - Wikipedia
Kaliuresis (/ˌkæljʊərˈiːsɪs/, /ˌkæli-/) or kaluresis (/ˌkæljʊərˈiːsɪs/) is the condition of excreting potassium in the urine. Thiazide diuretics are used to treat patients with heart failure. Their goal is to decrease the amount of salt (sodium chloride) in the body by decreasing the amount that the kidney reabsorbs. This excess sodium in the kidneys that is destined for excretion via urination can cause hyponatremia (low sodium level) and can lead to kaliuresis by increasing sodium-potassium exchange. Natriuresis Harrisons Principles of Internal Medicine, 16th edition Merriam-Webster entry Welling, Paul A. "Regulation of Renal Potassium Secretion: Molecular Mechanisms". Seminars in Nephrology. 33 (3): 215-228. doi:10.1016/j.semnephrol.2013.04.002 ...
https://en.wikipedia.org/wiki/Kaliuresis
Incorporating frailty in a multi-state model: Application to disease natural history modelling of adenoma-carcinoma in the...  Incorporating frailty in a multi-state model: Application to disease natural history modelling of adenoma-carcinoma in the...
TY - JOUR. T1 - Incorporating frailty in a multi-state model. T2 - Application to disease natural history modelling of adenoma-carcinoma in the large bowel. AU - Yen, Amy M F. AU - Chen, Tony H H. AU - Duffy, Stephen W.. AU - Chen, Chih Dao. PY - 2010/10. Y1 - 2010/10. N2 - Homogeneous multi-state models of disease progression have been widely used for designing and evaluating cancer screening programs. However, in screening for premalignant conditions of the cervix or large bowel, it is unlikely that all premalignant lesions have the same underlying propensity for progression. Incorporating frailty into multi-state models raises practical difficulties as it precludes the derivation of finite transition probabilities by matrix solution of the Kolmogorov equations. We address this problem by formulating a heterogeneous process as a series of homogeneous processes linked by transitions which are subject to heterogeneity (frailty). Continuous frailty and discrete mover-stayer models were developed. ...
https://tmu.pure.elsevier.com/en/publications/incorporating-frailty-in-a-multi-state-model-application-to-disea
Analysis of Multi-State Models with Mismeasured Covariates or Misclassified States  Analysis of Multi-State Models with Mismeasured Covariates or Misclassified States
Multi-state models provide a useful framework for estimating the rate of transitions between defined disease states and understanding the influence of covariates on transitions in studies of the disease progression. Statistical analysis of data from studies of disease progression often involves a number of challenges. A particular challenge is that the classification of the disease state may be subject to error. Another common problem is that there are many sources of heterogeneity in the data in which situation the assumption of time-homogeneous for common Markov models is not valid. In addition, it is common for discrete covariates subject to misclassification and the panel data collected from disease progression studies is time-dependence in the covariates. In Chapter 2, the progressive multi-state model with misclassification is developed to simultaneously estimate transition rates and account for potential misclassification. The performance of the maximum likelihood and pairwise likelihood ...
https://uwspace.uwaterloo.ca/handle/10012/9398
Survival Analysis of Patients with Gastric Cancer Undergoing Surgery at the Iran Cancer Institute: A Method Based on Multi...  Survival Analysis of Patients with Gastric Cancer Undergoing Surgery at the Iran Cancer Institute: A Method Based on Multi...
Survival Analysis of Patients with Gastric Cancer Undergoing Surgery at the Iran Cancer Institute: A Method Based on Multi-State Models Gastric cancer;intermediate event;multi-state model;proportional hazards model;survival rate; Background: Gastric cancer is one of the most common causes of cancer deaths all over the world and the most important reason for its high rate of death is its belated diagnosis at advanced stages of the disease. Events occur in patients which are regarded not only as themselves factors affecting patients survival but also which can be affected by other factors. This study was designed and implemented aiming to identify these events and to investigate factors affecting their occurrence. Materials and Methods: Data from 330 patients with gastric cancer undergoing surgery at the Iran Cancer Institute from 1995-1999 were analyzed. The survival time of these patients was determined after surgery and the effects of various factors including demographic, diagnostic and clinical as
http://koreascience.or.kr/article/JAKO201305981338473.page
Basic parametric analysis for a multi-state model in hospital epidemiology | BMC Medical Research Methodology | Full Text  Basic parametric analysis for a multi-state model in hospital epidemiology | BMC Medical Research Methodology | Full Text
In hospital-epidemiology the extended illness-death model, shown in Fig. 1, is a useful tool to study HAIs. The model allows both an etiological exploration of the events infection and in-hospital death and an investigation in terms of absolute risks.. In the extended illness-death model patients start in state 0 which is admission to the hospital. At this time none of the patients is infected. The patients remain in this state until they either leave the hospital without an HAI (state 2 if the discharge is alive, state 3 if the patient dies) or acquire an HAI. The concerned patients then move to state 1. In state 1 the patients remain under observation until discharge alive with an HAI (state 4) or death in the hospital with an HAI (state 5). The model is equivalent to the four-state model where death without and with an HAI are one state (state 3 and 5 are modelled as state 3) as well as discharge without and with an HAI (state 2 and 4 are modelled as state 2). In the four-state extended ...
https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-017-0379-4
Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach. - PubMed -...  Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach. - PubMed -...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
https://www.ncbi.nlm.nih.gov/pubmed/31609532
Event-history analysis, fall 2008 - mathstatKurssit - University of Helsinki Confluence  Event-history analysis, fall 2008 - mathstatKurssit - University of Helsinki Confluence
Andersen, P. K., Borgan, O, Gill, R. D., Keiding, N. Statistical Models Based on Counting Processes. Springer-Verlag, (1993).. Kalbfleisch, J. D., and R. L. Prentice. The Statistical Analysis of Failure Time Data. 2nd ed. New York: Wiley, (2002).. Per Kragh Andersen and Niels Keiding. Multi-state models for event history analysis. Statistical Methods in Medical Research 2002; 11: 91-115.. Per Kragh Andersen, Steen Z Abildstrom, Susanne Rosthøj. Competing risks as a multi-state model. Statistical Methods in Medical Research 2002; 11: 203-215.. ...
https://wiki.helsinki.fi/display/mathstatKurssit/Event-history+analysis%2C+fall+2008
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study - Global Genes  Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study - Global Genes
Please join the RARE Portal to add diseases of interest to your personal profile. By creating a profile, you can receive news, resources and updates related to this disease as well as many other benefits. ...
https://globalgenes.org/clinical_trials/use-of-biosimilar-nivestim-to-prevent-chemo-induced-neutropenia-real-life-study/
Plasma Viscosity | Viapath  Plasma Viscosity | Viapath
Plasma viscosity estimation is a reflection of changes in plasma proteins within the blood. The values from normal subjects are within a narrowly defined range and change when protein fractions are altered. The major influence on plasma viscosity is exerted by fibrinogen and immunoglobulins. The Viscometer determines viscosity by measuring the resistance of the plasma flow through a capillary under a constant vacuum ...
http://www.viapath.co.uk/our-tests/plasma-viscosity
Crohns disease - MATHEC  Crohn's disease - MATHEC
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO; Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP ...
https://www.mathec.com/en/publications/crohns-disease/
Prof. Dr. Jörg Henes | Universitätsklinikum Tübingen  Prof. Dr. Jörg Henes | Universitätsklinikum Tübingen
Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP, Wulffraat N, Buch M, Sampol A, Carreras E, Dubois B, Gruhn B, Güngör T, Pohlreich D, Schuerwegh A, Snarski E, Snowden J, Veys P, Fasth A, Lenhoff S, Messina C, Voswinkel J, Badoglio M, Henes J, Launay D, Tyndall A, Gluckman E, Farge D. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011 Aug 11;118(6):1693- ...
https://www.medizin.uni-tuebingen.de/de/das-klinikum/mitarbeiter/profil/1333
Patente US7457162 - Multi-state memory - Google Patentes  Patente US7457162 - Multi-state memory - Google Patentes
Maximized multi-state compaction and more tolerance in memory state behavior is achieved through a flexible, self-consistent and self-adapting mode of detection, covering a wide dynamic range. For high density multi-state encoding, this approach borders on full analog treatment, dictating analog techniques including A to D type conversion to reconstruct and process the data. In accordance with the teachings of this invention, the memory array is read with high fidelity, not to provide actual final digital data, but rather to provide raw data accurately reflecting the analog storage state, which information is sent to a memory controller for analysis and detection of the actual final digital data.
http://www.google.es/patents/US7457162?dq=flatulence
Patente US20040165431 - Novel multi-state memory - Google Patentes  Patente US20040165431 - Novel multi-state memory - Google Patentes
Maximized multi-state compaction and more tolerance in memory state behavior is achieved through a flexible, self-consistent and self-adapting mode of detection, covering a wide dynamic range. For high density multi-state encoding, this approach borders on full analog treatment, dictating analog techniques including A to D type conversion to reconstruct and process the data. In accordance with the teachings of this invention, the memory array is read with high fidelity, not to provide actual final digital data, but rather to provide raw data accurately reflecting the analog storage state, which information is sent to a memory controller for analysis and detection of the actual final digital data.
http://www.google.es/patents/US20040165431
Analyzing purchase incidence and brand choice by multi-state hazard models - Publikationsserver der Universität Regensburg  Analyzing purchase incidence and brand choice by multi-state hazard models - Publikationsserver der Universität Regensburg
After introducing the main topic of this paper (the study of purchase incidence and brand choice decisions) we explain basic concepts of hazard models and describe the probability distributions considered in the empirical study presented later. After a review of pure purchase incidence (product category) models as well as integrated models that include brand choice as well, we specify and discuss properties of one-state and multi-state hazard models, respectively. Our conclusions are based on applying hazard models to household scanner data. ...
https://epub.uni-regensburg.de/8375/
Network | Information | Binary and Multi-state data  Network | Information | Binary and Multi-state data
Note: An important Network software prerequisite is fully aligned sequence data (the same applies for other phylogenetic software like TCS). Please use the DNA Alignment software for aligning FASTA data and for correctly formatting these into Network binary rdf or Network multi-state rdf files ...
http://www.fluxus-engineering.com/alignfastardf.htm
SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nations...  SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nation's...
Health,... Nursing Home Workers in PA MI IL FL OH MD WI WA Join Forces ... Buyout ...WASHINGTON Oct. 3 -- In an effort to improve...In states where Manor Care has large operations includingPennsylvani...,SEIU,Launches,Multi-State,Grassroots,Campaign,Calling,on,the,Carlyle,Group,to,Put,Care,Above,Profits,in,Buyout,of,Nations,Largest,Nursing,Home,Chain,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
http://www.bio-medicine.org/medicine-news-1/SEIU-Launches-Multi-State-Grassroots-Campaign-Calling-on-the-Carlyle-Group-to-Put-Care-Above-Profits-in-Buyout-of-Nations-Largest-Nursing-Home-Chain-2784-1/
Piero Olliaro - DNDi  Piero Olliaro - DNDi
Dr Piero OlliaroHead of intervention and implementation research at TDRFormer member of the Drugs for Neglected Diseases working groupPiero Olliaro earned his M
https://www.dndi.org/about-dndi/friends-of-dndi/piero-olliaro/
The association between type 2 diabetes mellitus, hip fracture, and post-hip-fracture mortality: a multi-state cohort analysis ...  The association between type 2 diabetes mellitus, hip fracture, and post-hip-fracture mortality: a multi-state cohort analysis ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
https://www.ndorms.ox.ac.uk/publications/724569
Multi-state grazing conference set - Farm and Dairy  Multi-state grazing conference set - Farm and Dairy
The cost of the conference is $65 ($70 after Feb. 7) for the first person from each farm and $55 ($65 after Feb. 7) for each additional person from the farm. This fee includes registration, breaks, trade show, proceedings and Tuesday lunch. The (optional) dinner on Monday evening is $15 ...
https://www.farmanddairy.com/news/multi-state-grazing-conference-set/6159.html
Members Appointed to New Tick-Borne Disease Working Group | HHS.gov  Members Appointed to New Tick-Borne Disease Working Group | HHS.gov
The U.S. Department of Health and Human Services announced today the appointment of 14 members to the new Tick-Borne Disease Working Group.
https://www.hhs.gov/about/news/2017/11/22/members-appointed-new-tick-borne-disease-working-group.html
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter,...  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter,...
TY - JOUR. T1 - First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer. T2 - A multicenter, double-blind, placebo-controlled phase III study. AU - Vogel, Charles. AU - Wojtukiewicz, Marek Z.. AU - Carroll, Robert R.. AU - Tjulandin, Sergei A.. AU - Barajas-Figueroa, Luis Javier. AU - Wiens, Brian L.. AU - Neumann, Theresa A.. AU - Schwartzberg, Lee S.. PY - 2005/2/20. Y1 - 2005/2/20. N2 - Purpose: We evaluated the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia associated with docetaxel in breast cancer patients. Patients and Methods: Patients were randomly assigned to either placebo or pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle of 100 mg/m2 docetaxel. The primary end point was the percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C and neutrophil count , 0.5 × 109/L on the same day of the fever or the day after). Secondary end points were ...
https://miami.pure.elsevier.com/en/publications/first-and-subsequent-cycle-use-of-pegfilgrastim-prevents-febrile-
Ronald E. Gangnon, PhD | Population Health Sciences  Ronald E. Gangnon, PhD | Population Health Sciences
Ronald Gangnon is Professor of Biostatistics with a joint appointment in the Department of Population Health Sciences and the Department of Biostatistics & Medical Informatics. He also has an affiliate appointment in the Department of Statistics. Dr. Gangnon earned his BA degree in Mathematics and Economics at the University of Minnesota-Duluth (1992) and his MS (Statistics, 1994) and PhD (Statistics with emphasis in Biostatistics, 1998) from the University of Wisconsin-Madison. Dr. Gangnons research interests are in the development and application of statistical methods in clinical and epidemiologic research. Areas of methodologic interest include spatial epidemiology, with emphasis on detection and modeling of spatial and spatio-temporal clusters, syndromic surveillance, age-period-cohort modeling, multi-state models and ranking. Dr. Gangnon serves as Director of the Biostatistics Core for the Childhood Origins of ASThma (COAST) project, a prospective birth cohort study of early childhood ...
https://pophealth.wisc.edu/ronald-gangnon
MULTISTATE: Stata module to perform multi-state survival analysis  MULTISTATE: Stata module to perform multi-state survival analysis
Downloadable! multistate provides a set of commands for multi-state survival analysis. This includes msset, a data preparation tool which converts a dataset from wide (one observation per subject, multiple time and status variables) to long (one observation for each transition of which a subject is at risk), and predictms, which calculates transition probabilities, and many other useful measures of absolute risk, following the fit of a model using streg, or stpm2. predictms allows different families of models to be specified for each transition. All quantities are calculated through simulation, including confidence intervals. Differences and ratios across covariate patterns can be calculated.
https://ideas.repec.org/c/boc/bocode/s458207.html
Febrile Neutropenia  Febrile Neutropenia
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
https://lookfordiagnosis.com/mesh_info.php?term=Febrile+Neutropenia&lang=1
12 indicted in multi-state drug trafficking conspiracy | Drugs-Forum  12 indicted in multi-state drug trafficking conspiracy | Drugs-Forum
CLEVELAND - Twelve defendants were indicted Tuesday in a major drug trafficking conspiracy in which large shipments of cocaine were flown by private chartered airplanes from Texas to Cleveland....
https://drugs-forum.com/ams/12-indicted-in-multi-state-drug-trafficking-conspiracy.17757/
Lenalidomide Plus Chemotherapy for AML - Full Text View - ClinicalTrials.gov  Lenalidomide Plus Chemotherapy for AML - Full Text View - ClinicalTrials.gov
After undergoing screening procedures to confirm that you are eligible to participate in the research study you will be admitted to the hospital. You will likely receive the majority of treatment on an inpatient basis. You will remain in the hospital for at least Days 4-8 and will be discharged at the discretion of your study doctor. It is likely that you will be hospitalized for several weeks due to the risk of infection after chemotherapy.. Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have relapsed or refractory AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.. If you take part in this study you will be given a study drug-dosing calendar. There is only one cycle of treatment, ...
https://clinicaltrials.gov/ct2/show/NCT01681537
Lenalidomide Plus Chemotherapy for AML - Tabular View - ClinicalTrials.gov  Lenalidomide Plus Chemotherapy for AML - Tabular View - ClinicalTrials.gov
After undergoing screening procedures to confirm that you are eligible to participate in the research study you will be admitted to the hospital. You will likely receive the majority of treatment on an inpatient basis. You will remain in the hospital for at least Days 4-8 and will be discharged at the discretion of your study doctor. It is likely that you will be hospitalized for several weeks due to the risk of infection after chemotherapy.. Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have relapsed or refractory AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.. If you take part in this study you will be given a study drug-dosing calendar. There is only one cycle of treatment, ...
https://clinicaltrials.gov/ct2/show/record/NCT01681537
Candidates make final Super Tuesday push - politics - Decision 08 | NBC News  Candidates make final Super Tuesday push - politics - Decision '08 | NBC News
Buoyed by cheering crowds and bolstered by more than $1.3 million a day in TV ads, candidates made their last pleas for votes before the multi-state contests begin.
http://www.nbcnews.com/id/22990628/ns/politics-decision_08/
Udostępnij ten post  Udostępnij ten post
Neulasta is approved as a treatment for patients undergoing chemotherapy, to decrease the incidence of infection by febrile neutropenia. It is administered...
https://www.ipsbeyond.pl/topic/729-invisionizeeu-neulasta-neulasta/
Ivo Abraham, PhD, RN | College of Pharmacy - University of Arizona  Ivo Abraham, PhD, RN | College of Pharmacy - University of Arizona
Abraham, I., MacDonald, K., Song, M.K., Ciesielski, G., Pacheco, C., Lee, C., Cholette, M., Kinsey, K., Speaks, P., Hermans, C., Brié, H., Reel, S., Van der Niepen, P., Yee, B., & Vancayzeele, S. (in press). Patient- and physician-level determinants of blood pressure response to treatment in normal and overweight patients. (the PREVIEW Study). Nutrition, Metabolism, & Cardiovascular Diseases.. Aapro, M., Cornes, P., & Abraham, I. (in press). Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. Journal of Oncology Pharmacy Practice.. Gesualdo, L., London, G., Turner, M., Lee, C., MacDonald, K., Covic, A., Zaoui, P., Combe, C., Dellana, F., Muenzberg, M., & Abraham, I. (in press). A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anemia in hemodialysis patients: ...
http://www.pharmacy.arizona.edu/directory/ivo-abraham-phd-rn
LDA President Appointed to HHS Tick-Borne Disease Working Group  LDA President Appointed to HHS Tick-Borne Disease Working Group
Lyme Disease Association was founded in 1991 with a mission of expanding research and funding for Lyme Disease nation wide. Visit our site to find out more.
https://lymediseaseassociation.org/news/1790-lda-president-appointed-to-hhs-tick-borne-disease-working-group
Pfizer acquires FDA approval for new biosimilar IXIFI - Pharmaceutical Technology  Pfizer acquires FDA approval for new biosimilar IXIFI - Pharmaceutical Technology
The FDA approved IXIFI based on the overall results obtained during the multi-national, randomised, double blind, two-arm, parallel group Phase III REFLECTIONS B537-02 trial conducted in subjects with moderate-to-severe active rheumatoid arthritis.. Results indicated high degree of similarity between IXIFI and the reference product Remicade, which was given as an intravenous injection combined with methotrexate.. Performed to assess the safety, efficacy and immunogenicity of IXIFI, the trial met its primary endpoint of ACR20 response at week 14.. Outside the US, Pfizer markets three biosimilar medicines, INFLECTRA (infliximab), Retacrit (epoetin zeta) and Nivestim (filgrastim).. In addition, the firms portfolio includes a biosimilars pipeline with 13 distinct biosimilar molecules that are in different stages of development.. The firm also markets Celltrions INFLECTRA (infliximab-dyyb) in select markets, including the US.. ...
http://www.pharmaceutical-technology.com/news/pfizer-acquires-fda-approval-new-biosimilar-ixifi/
Study Finds CISNE Model Effective for Guiding Treatment-Setting Decisions for Febrile Neutropenia  Study Finds CISNE Model Effective for Guiding Treatment-Setting Decisions for Febrile Neutropenia
A new study comparing 2 risk stratification models found that the Clinical Index of Stable Febrile Neutropenia (CISNE) Model is useful for identifying low-risk patients with febrile neutropenia, but the combination of the CISNE Model with the Multinational Association of Supportive Care in Cancer Risk Index Score may help emergency physicians cope with febrile neutropenia more confidently.
https://www.ajmc.com/newsroom/study-finds-cisne-model-effective-for-guiding-treatmentsetting-decisions-for-febrile-neutropenia
Full Design Automation of Multi-State RNA Devices to Program Gene Expression Using Energy-Based Optimization - Semantic Scholar  Full Design Automation of Multi-State RNA Devices to Program Gene Expression Using Energy-Based Optimization - Semantic Scholar
Small RNAs (sRNAs) can operate as regulatory agents to control protein expression by interaction with the 5 untranslated region of the mRNA. We have developed a physicochemical framework, relying on base pair interaction energies, to design multi-state sRNA devices by solving an optimization problem with an objective function accounting for the stability of the transition and final intermolecular states. Contrary to the analysis of the reaction kinetics of an ensemble of sRNAs, we solve the inverse problem of finding sequences satisfying targeted reactions. We show here that our objective function correlates well with measured riboregulatory activity of a set of mutants. This has enabled the application of the methodology for an extended design of RNA devices with specified behavior, assuming different molecular interaction models based on Watson-Crick interaction. We designed several YES, NOT, AND, and OR logic gates, including the design of combinatorial riboregulators. In sum, our de novo approach
https://www.semanticscholar.org/paper/Full-Design-Automation-of-Multi-State-RNA-Devices-Rodrigo-Landrain/6ff726db6f6a956481da3fdc2a3c1c181f06f866
Attorney General Corbett Announces $36.7 Million Multi-State Settlement With CVS/Caremark in National Dosage-Switching Inv... (...  Attorney General Corbett Announces $36.7 Million Multi-State Settlement With CVS/Caremark in National Dosage-Switching Inv... (...
Health,... HARRISBURG Pa. March 18 -- Attorney Gene...Corbett said the settlement follows a joint federal and stateinvestig...According to the settlement CVS was accused of making wholesalechang...Corbett said that Pennsylvania will receive $495628 from CVS/Caremark...,Attorney,General,Corbett,Announces,$36.7,Million,Multi-State,Settlement,With,CVS/Caremark,in,National,Dosage-Switching,Investigation,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
http://www.bio-medicine.org/medicine-news-1/Attorney-General-Corbett-Announces--2436-7-Million-Multi-State-Settlement-With-CVS-Caremark-in-National-Dosage-Switching-Investigation-14641-1/
Febrile Neutropenia - Urinary Tract - Barnard Health Care  Febrile Neutropenia - Urinary Tract - Barnard Health Care
Febrile neutropenia is defined as: (1) a single oral temperature above 38.3°C or a temperature of 38.0°C or higher lasting longer than 1 h, and (2) an absolute neutrophil count below 500 cells/^l (Hughes et al. 2002). Of bladder cancer patients undergoing CMV or MVAC chemotherapy regimens, 10 % -14 % meet these established criteria (Gilligan et al. 2003). The importance of febrile neutropenia lies in the fact that infection is the most common cause of fever in the neutropenic setting (50 %) and, in turn, the leading cause of chemotherapy-related death (Schimpff 1986). As such, fever in the context of neutropenia is considered to reflect active infection until proven otherwise.. Was this article helpful?. ...
https://www.barnardhealth.us/urinary-tract/febrile-neutropenia.html
WHO | Partnerships  WHO | Partnerships
DCE coordinates the WHO Communicable Diseases Working Group on Emergencies (CD-WGE), which includes WHO experts across many departments on relevant diseases. The CD-WGE provides expert advice for the development of guidelines and training material, and helps set standards and prioritize interventions for communicable diseases in acute and protracted humanitarian emergencies. ...
http://www.who.int/diseasecontrol_emergencies/partnerships/en/
A Message From the Interventional Council and Member Section - American College of Cardiology  A Message From the Interventional Council and Member Section - American College of Cardiology
Skip Anderson, MD, FACC has been working to build a database of speakers who can respond to invitations to the College from our international colleagues and facilitate collaboration and learning on an international level. Dr. Anderson has also asked for volunteers to help in this endeavor, which is strongly endorsed by the ACC.. The council is also in the early stages of forming a structural heart disease working group, led by Joaquin Cigarroa, MD, FACC. This is a heart team concept and will include members with collaborative special interests outside of interventional cardiology, including but not limited to: general cardiologists, adult congenital cardiologists, cardiac surgeons, echocardiography/imaging specialists, electrophysiologists, cardiovascular team members, fellows in training, and anesthesiologists.. The council and section would like to continue to see a strong relationship between the ACC (aka, House of Cardiology) and Society for Cardiac Angiography and Interventions (SCAI) (aka, ...
http://www.acc.org/latest-in-cardiology/articles/2015/04/29/09/16/a-message-from-the-interventional-council-and-member-section
PENGGUNAAN ANTIBIOTIKA PADA PASIEN LEUKEMIA AKUT DEWASA DENGAN FEBRILE NEUTROPENIA SETELAH PEMBERIAN KEMOTERAPI AGRESIF DI...  PENGGUNAAN ANTIBIOTIKA PADA PASIEN LEUKEMIA AKUT DEWASA DENGAN FEBRILE NEUTROPENIA SETELAH PEMBERIAN KEMOTERAPI AGRESIF DI...
PENGGUNAAN ANTIBIOTIKA PADA PASIEN LEUKEMIA AKUT DEWASA DENGAN FEBRILE NEUTROPENIA SETELAH PEMBERIAN KEMOTERAPI AGRESIF DI RUMAH SAKIT KANKER DHARMAIS JAKARTA
http://journal.uad.ac.id/index.php/Media-Farmasi/article/view/1877
中国科学院大连化学物理研究所机构知识库(DICP OpenIR): Multi-state Targeting Machinery Govern the Fidelity and Efficiency of Protein Localization  中国科学院大连化学物理研究所机构知识库(DICP OpenIR): Multi-state Targeting Machinery Govern the Fidelity and Efficiency of Protein Localization
Proper localization of newly synthesized proteins is essential to cellular function. Among different protein localization modes, the signal recognition particle (SRP) and SRP receptor (SR) constitute the conserved targeting machinery in all three life kingdoms and mediate about one third of the protein targeting reactions. Based on experimental and computational studies, a detailed molecular model is proposed to explain how this molecular machinery governs the efficiency and fidelity of protein localizations. In this targeting machinery, two distinct SRP GTPases are contained into the SRP and SR that are responsible to the interactions between SRP and SR. These two GTPases can interact with one another through a series of sequential and discrete interaction states that are the early intermediate formation, stable complex association, and GTPase activation. In contrast to canonical GTPases, a floppy and open conformation adopted in free SRP GTPases can facilitate efficient GTP/GDP exchange ...
http://cas-ir.dicp.ac.cn/handle/321008/145509
BrainStars Multi-state Genes  BrainStars Multi-state Genes
TF=Transcription Factor; Ch=Channel; GPCR=GPCR; CA=Cell Adhesion; EM=Extracellular Matrix; SP=Structural Protein; Ng=Neurogenesis; Hox=Homeobox; NR=Nuclear Receptor; NH/NT=NH/NT; AG=Axon Guidance; SLC=SLC Transporter; Fox=Forkhead ...
http://poabf.brainstars.org/multistate/high/Pir
Florida calling for catastrophe fund - latimes  Florida calling for catastrophe fund - latimes
Frustrated by inaction in Washington, Florida officials this week are asking other states to join them in setting up an insurance catastrophe fund.If established, a multi-state fund would bail out
http://articles.latimes.com/2007/feb/14/nation/na-disaster14
Buffer Reference Center | China-Mainland | Sigma-Aldrich  Buffer Reference Center | China-Mainland | Sigma-Aldrich
Na2HPO4 • 2H2O, M. wt. 178.05; 0.2M-solution contains 35.61 g/l. Na2HPO4 • 12H2O, M. wt. 358.22; 0.2M -solution contains 71.64 g/l. NaH2PO4 • H2O, M. wt. 138.01; 0.2M-solution contains 27.6 g/l. NaH2PO4 • 2H2O, M. wt. 156.03; 0.2M-solution contains 31.21 g/l ...
https://www.sigmaaldrich.com/china-mainland/zh/life-science/core-bioreagents/biological-buffers/learning-center/buffer-reference-center.html
About Endo-ERN | Endo-ERN  About Endo-ERN | Endo-ERN
About Endo-ERN , Endo-ERN, About the Network Endo-ERN aims to improve access to high-quality healthcare for patients with hormonal disorders. For this purpose the education of Reference Centers (RCs) across Europe will be supported
https://endo-ern.eu/about/about-endo-ern/
Immune signatures of CRS and neurologic events in subjects with refractory Diffuse Large B-Cell Lymphoma treated with KTE-C19...  Immune signatures of CRS and neurologic events in subjects with refractory Diffuse Large B-Cell Lymphoma treated with KTE-C19...
Refractory Diffuse Large B-Cell Lymphoma - immune signatures of CRS and neurologic events in subjects treated with KTE-C19 in the ZUMA-1 trial: presentation at the AACR 2017 annual meeting
https://lymphomahub.com/medical-information/aacr-2017-zuma-1-trial-immune-signatures-of-crs-and-neurologic-events-in-subjects-with-refractory-diffuse-large-b-cell-lymphoma-treated-with-kte-c19
Seventh annual international Survival Analysis for Junior Researchers conference (SAfJR2018) - Netherlands Society for...  Seventh annual international Survival Analysis for Junior Researchers conference (SAfJR2018) - Netherlands Society for...
Leiden hosts the annual international conference Survival Analysis for Junior Researchers on 24-26 April, 2018. This conference is aimed at career-young statisticians with an interest in the application and development of time-to-event analysis and related topics. This three-day event provides a unique opportunity for participants to present and discuss their work with peers at a similar stage in their careers in a relaxed and friendly environment.. The event includes a tutorial on multi-state models by Prof. dr. Hein Putter (Leiden University Medical Center), talks from keynote speakers Dr. Maja Pohar Perme (University of Ljubljana) and Dr. Birgit Lissenberg-Witte (VU University Medical Center, Amsterdam), as well as poster sessions, a welcome reception and a conference dinner!. The conference aims to bring together researchers and statisticians working in different areas of survival analysis who are in the early stages of their career. This includes:. - Career-young researchers and ...
http://vvs-or.nl/en/menu/Home/Calendar/24thofapril2018/2950/LeidentheNetherlands/SeventhannualinternationalSurvivalAnalysisforJuniorResearchersconferenceSAfJR2018?cal=9-2017&
CytoSorbents to Exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery  CytoSorbents to Exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company, announced that it will exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery in Freiburg, Germany from February 9-12, 2014. The conference is in cooperation with the Austrian and Swiss Societies for Thoracic and Cardiovascular Surgery.
http://www.andhranews.net/Business/2014/CytoSorbents-Exhibit-43rd-Annual-Meeting-German-5345.htm
CytoSorbents to Exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery  CytoSorbents to Exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery
CytoSorbents Corporation , a critical care immunotherapy company, announced that it will exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery in Freiburg, Germany ...
https://finance.yahoo.com/news/cytosorbents-exhibit-43rd-annual-meeting-132431282.html
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated...  A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated...
This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.This study (CC-
http://www.knowcancer.com/cancer-trials/NCT00478777/
MPI CE: Homepage  MPI CE: Homepage
Knaden M. (2017). Navigating in an extreme environment: how desert ants forage efficiently. Talk presented at 27th Annual Conference of the German Society for Cytometry 27th Annual Conference of the German Society for Cytometry Jena, Germany • October 2017 Register New Login Conference Time: 10/Oct/2017 9:02:40 am CET 27th Annual Conference of the German Society for Cytometry, Ernst-Abbe-Hochschule Jena, Jena, ...
http://www.ice.mpg.de/ext/index.php?id=hopa&pers=makn3698&d=han&li=ice&pg=pres
Febrile neutropenia with Neurontin  Febrile neutropenia with Neurontin
Feeling FEBRILE NEUTROPENIA while using Neurontin? FEBRILE NEUTROPENIA Causes, Patient Concerns and Latest Treatments and Neurontin Reports and Side Effects.
http://patientsville.com/i.htm?q=FEBRILE%20NEUTROPENIA&mp=Neurontin
Download Selling Sex In The Reich Prostitutes In German Society 1914 1945  Download Selling Sex In The Reich Prostitutes In German Society 1914 1945
To need how pharmaceutical download selling sex in the reich were helped during insights of data of drug, it receives adjustable to click into medical Dream& users that have forecasted dedicated since Darwin. detail disease has not amazing, but why is this thinking started for by back highly minimum castles? As an download selling, philosophy; meteorology; 85 success of the 62,000 extreme dull reviews cover to particularly six other members.
http://patriciasyarns.com/ebook/download-selling-sex-in-the-reich%3A-prostitutes-in-german-society%2C-1914-1945
GMS | 80th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery | Immunmodulation von nasalen...  GMS | 80th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery | Immunmodulation von nasalen...
Der Einfluss von Staphylokokken bei der chronischen Rhinosinusitis ist nicht gut untersucht. Grunds tzlich werden drei verschiedene Formen der Schleimhaut-Staphylokokken Interaktion unterschieden: intrazellul re Persistenz, Infektion und Besiedlung. Der erste Schritt des Staphylokokken-Schleimaut Kontakts, ob Infektion oder Besiedlung, postuliert aber die berwindung der lokalen Wirt-Immunantwort. Zur Untersuchung dieses Mechanismus wurde die Zytokin Expression von Interleukin (IL)-8, growth-related oncogene (GRO)-α und IL-6 nach Stimulation mit Trypsin und Zellkultur berst nden verschiedener S. aureus St mme and Phenotypen an nasalen Epithelzellkulturen untersucht. Die Zytokin Synthese wurde einem Glukokortikosteroid, einem Serin-Proteasen Inhibitor und einem Zystein-Proteasen Inhibitor gehemmt. Die Signaltransduktions-Kaskaden wurden f r die phosphorylierten Formen der MAP-Kinasen (PI3 Kinase, extrazellul r signal-regulierte Kinase, p38) und dem nukle ren Transkriptionsfaktor NFκB betimmt. ...
http://www.egms.de/static/en/meetings/hnod2009/09hnod154.shtml
A non-interventional, comparative study of NivestimTM with reference filgrastim and pegfilgrastim in febrile neutropenia -...  A non-interventional, comparative study of NivestimTM with reference filgrastim and pegfilgrastim in febrile neutropenia -...
This non-interventional, cohort study compared the efficacy of NivestimTM with reference filgrastim and pegfilgrastim in female patients with early breast
http://adisinsight.springer.com/trials/700277308?error=cookies_not_supported&code=fc233c3c-3576-486e-8698-ef1aa1927fb4
DE69614545T2 - Stacked burned diode for use with a multi-state material in a non-volatile storage cell - Google Patents  DE69614545T2 - Stacked burned diode for use with a multi-state material in a non-volatile storage cell - Google Patents
H01L27/24-Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including solid state components for rectifying, amplifying or switching without a potential-jump barrier or surface barrier, e.g. resistance switching non-volatile memory structures ...
https://patents.google.com/patent/DE69614545T2/en
Informationen 2014 - AIO Arbeitsgemeinschaft Internistische Onkologie  Informationen 2014 - AIO Arbeitsgemeinschaft Internistische Onkologie
Derzeit aktiv sind folgende Register. Register für Leydig-Zell-Tumoren (Kontakt: [email protected]) Register für Patienten mit primärer „poor risk" Erkrankung nach IGCCCG: konventionell und hochdosierte Chemotherapie (Kontakt: [email protected], [email protected]). Register zur GOP-Chemotherapie bei Patienten mit refraktärer und mehrfach rezidivierter Erkrankung (Kontakt: [email protected], [email protected]); Präsentation Zwischenergebnisse auf dem DGHO 2014 in HH; Rekrutierung noch bis 31.12.14.. Register für Seminom-Patienten mit Rezidiv nach adjuvanter Chemotherapie mit Carboplatin (Kontakt: [email protected] ...
http://aio-portal.de/index.php/informationen-2014-450.html
Administration office | Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie  Administration office | Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie
The administration office of the German Society for Thoracic and Cardiovascular Surgery is located in the Langenbeck-Virchow-Haus (LVH) at the heart of Berlin.. Staff at the administration office will be pleased to answer your questions or provide information from 9 am to 3 pm, Monday to Friday.. ...
https://www.dgthg.de/en/node/112
Infection Prevention Program Mission and Value Statement | AORN Facility Reference Center  Infection Prevention Program Mission and Value Statement | AORN Facility Reference Center
The AORN Facility Reference Center is the online home of the evidence-based AORN Guidelines for Perioperative Practice and associated tools for OR teams.
https://aornguidelines.org/tool/content?gbosid=426365
Evidence Based Information | Nursing Reference Center | EBSCO  Evidence Based Information | Nursing Reference Center | EBSCO
EBSCOs Nursing Reference Center contains Evidence-Based Information. See EBSCOs 7-Step Evidence-Based methodology and editorial process.
https://www.ebscohost.com/nursing/products/nursing-reference-center/nursing-reference-center-editorial-policies
Feds: Drug ring had enough cheap fentanyl to kill 14 million  Feds: Drug ring had enough cheap fentanyl to kill 14 million
Law enforcement in Virginia said theyve taken down a multi-state drug ring and seized enough fentanyl from China to kill 14 million people
https://www.detroitnews.com/story/news/nation/2019/08/29/feds-drug-ring-enough-cheap-fentanyl-kill-million/40046225/
The Day - Keeping track of living fossils - News from southeastern Connecticut  The Day - Keeping track of 'living fossils' - News from southeastern Connecticut
Volunteers gathered Thursday evening to tag horseshoe crabs as part of Project Limulus, a multi-state, multi-year effort to collect data on this important
http://www.theday.com/article/20130526/NWS01/305269938/1070/ent
The Day - Keeping track of living fossils - News from southeastern Connecticut  The Day - Keeping track of 'living fossils' - News from southeastern Connecticut
Volunteers gathered Thursday evening to tag horseshoe crabs as part of Project Limulus, a multi-state, multi-year effort to collect data on this important
http://www.theday.com/apps/pbcs.dll/article?AID=/20130526/NWS01/305269938/1070/ENT19&CSLoginOnly=true
Establishment of the Multi-State Plan Program for the Affordable Insurance Exchanges: Resources Database: Resources: APIAHF  Establishment of the Multi-State Plan Program for the Affordable Insurance Exchanges: Resources Database: Resources: APIAHF
AA and NHPI communities are extraordinarily diverse with dozens of different cultures and languages. Discrimination related to culture, language, affordability, and restrictions on legal immigrants continue to impose major barriers to accessing quality health care for AAs and NHPIs. The proposed regulations make clear that neither the Multi-State Plan Program (MSPP), nor issuers of Multi-State Plans (MSPs), nor MSPs can discriminate based on race, color, national origin, disability, age, sex, gender identity, or sexual orientation.1 Since robust enforcement of non-discrimination procedures including appropriate translation of health materials is crucial for our communities, APIAHF joins with The Leadership Conference on Civil and Human Rights in commending OPM for including the full range of classes protected against discrimination under the Affordable Care Act (ACA).. ...
http://www.apiahf.org/resources/resources-database/establishment-multi-state-plan-program-affordable-insurance-exchanges
German Society for Tissue Transplantation - IAPB  German Society for Tissue Transplantation - IAPB
For more than 20 years, the non-profit German Society for Tissue Transplantation (DGFG) has been supplying patients in Germany with high-quality and safe cornea, amniotic membrane, cardiovascular and musculoskeletal tissue transplants. Since the start, the development of tissue donation in Germany as well as supporting the tissue banks and transplantation centres have been the core…. Read more. ...
https://www.iapb.org/news_tags/german-society-for-tissue-transplantation/
Febrile Neutropenia  Febrile Neutropenia
... occurs in compromised immune systems due to a low number of leukocytes, especially granulocytes. Patients with a declining number of granulocytes after chemotherapy, can during bacterial sepsis, quickly develop extensive neutropenia and become critically ill. Febrile neutropenia can be a life-threatening condition.. A patient with neutropenia and simultaneous fever or clinical suspicion of systemic infection should be treated as quickly as possible with broad spectrum antibiotics including gram-negative and gram-positive coverage as soon as the required microbiological samples are taken.. The clinical situation is most critical in patients who have not yet started antibiotic treatment. When broad-spectrum antibiotic treatment is started, monitoring the fever may be permitted. Fever is often the only symptom. Some have septicemia without fever. One should therefore also be aware of other symptoms such as lethargia, diarrhea, or visible sign of infection. The local clinical ...
http://oncolex.org/Prosedyrer/TREATMENT/ComplicationTreatment/FebrileNeutropenia?lg=procedure
DGfZ - Deutsche Gesellschaft für Zytometrie  DGfZ - Deutsche Gesellschaft für Zytometrie
After a successful conference last year the Annual Meeting of the German Society will come back to Jena again in 2018. DGfZ president and conference chair Wolfgang Fritzsche is looking forward to host the conference again and hopes to welcome many old and new participants, exhibitors and presenters to Jena. This time the conference will be held in the foyer of the Friedrich Schiller University located in Jenas vibrant city centre and the Leibniz Institute of Photonic Technologies will again be the organizer of the event. The scientific program is put together at the moment and the schedule and the website will be updated constantly, so make sure to check back here regularly to get all the latest information.. Life in Focus. The annual conference of the German Society for Cytometry provides a platform for interdisciplinary exchange in basic research, clinical and industrial developments. Aim of the conference is the promotion of methodological and technical innovation in flow cytometry (FCM), ...
http://www.dgfz.org
Journal medizinischegenetik | German Society of Human Genetics  Journal 'medizinischegenetik' | German Society of Human Genetics
publishes the journal medizinischegenetik.. Since 1989, the quarterly journal medizinischegenetik, appreciated as forum for GfH members, gained in importance for the postgraduate and continuous medical education in Human Genetics. Quarterly, brochures on special issues of Human Genetics are published ...
https://gfhev.de/en/publications/zeitschrift.htm
Gunhildur Gudnadottir - University of Gothenburg, Sweden  Gunhildur Gudnadottir - University of Gothenburg, Sweden
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, Journal article 2018 ...
https://clinsci.gu.se/Institute_of_clinical_sciences/otorhinolaryngology/dept-of-otorhinolaryngology/?tipFriend=true&tipUrl=http%3A%2F%2Fclinsci.gu.se%2FInstitute_of_clinical_sciences%2Fotorhinolaryngology%2Fdept-of-otorhinolaryngology%2F%3FlanguageId%3D100001%26userId%3Dxgudgu&languageId=100001&userId=xgudgu
Billevesées: April 2009  Billevesées: April 2009
The two make an interesting contrast, and the most immediate impression one gets is simply that an oppressed community that procreates and identifies itself publicly will leave more stuff to the future than will one that is childless and hidden. The Jewish collection is vast, housed in a brilliantly designed structure that, seen from above, cuts a jagged slash across the landscape, almost like a Star of David thats been ripped open. The architect, Daniel Libeskind, incorporates empty spaces in the galleries, air shafts and unadorned nooks, as a reminder of absence - the thousands of Jews who were removed from German society, and from existence, by generations of bigots. Exhibits demonstrate that the Nazis were hardly the first, only the most systematic, to scapegoat and attack the Jews. Yet the vitality of the community shines through consistently (You wont let us hold most kinds of jobs? So be it: well become the worlds greatest traders, bankers, and doctors), and there is much to celebrate ...
http://billmadison.blogspot.com/2009/04/
As California goes on gay marriage ... - LA Times  As California goes on gay marriage ... - LA Times
Jon W. Davidson says the California court s decision will influence judicial and legislative proceedings across the country but probably won t affect the presidential election. Glen Lavy predicts that the court s ruling will spark a multi-state backlash similar to the one in 2004.
http://www.latimes.com/opinion/la-op-lavy-davidson20-2008may20-story.html
Issues  Issues
We drive change at the local, state, and national levels. From litigating and shaping policies in Illinois to training and convening multi-state networks of public interest attorneys, we work with and for the communities we serve to make equal justice and economic opportunity a reality.. ...
https://www.povertylaw.org/issues/
Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving...  Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving...
To compare the efficacy and safety of Day 2 (D2) once a cycle pegfilgrastim with Intermittent Every Other Days of 5 Shot (D3-11) filgrastim in early breast
http://adisinsight.springer.com/trials/700268053?error=cookies_not_supported&code=22710c89-49a5-44e7-bcc2-94436ba58297
Preventing Infection in Patients With Neutropenia: Q&A With Dr Ruben A. Mesa  Preventing Infection in Patients With Neutropenia: Q&A With Dr Ruben A. Mesa
Individuals who develop neutropenia are at higher risk of infection, and they should understand the symptoms to look for that might mean they need to seek urgent medical care, explained Ruben A. Mesa, MD, of the Mayo Clinic.
http://www.ajmc.com/newsroom/preventing-infection-in-patients-with-neutropenia-qa-with-dr-ruben-a-mesa
GMS | 57th Annual Meeting of the German Society of Neurosurgery Joint Meeting with the Japanese Neurosurgical Society | About...  GMS | 57th Annual Meeting of the German Society of Neurosurgery Joint Meeting with the Japanese Neurosurgical Society | About...
We are glad that the top specialists for example the German Minister of Justice, Mrs. Zypries, agreed to come for statements and discussion of this important topic.. The main topics document the state of art and the free topics reveal developments, research and special aspects of neuroscience.. Just like every year we had to select the papers because of a great number of abstract submissions. The members of the progamme committee did their very best. I would like to express my gratitude to all of them for their efficient work. I also wish to thank the secretary of the meeting and the editors who made the edition of the abstracts possible.. Prof. Dr. D. ...
http://www.egms.de/static/en/meetings/dgnc2006/about.htm
One dead, 24 sick from multi-state Listeria outbreak linked to soft cheeses | Fox 59  One dead, 24 sick from multi-state Listeria outbreak linked to soft cheeses | Fox 59
(CNN) - A Listeria outbreak linked to soft cheeses has caused 24 cases of illness in nine states, including one death and one fetal death, the CDC said Friday. Twenty-one of those who became ill have been hospitalized. The agency is working with state health officials and the FDA to investigate the outbreak that dates […]
https://fox59.com/news/health/one-dead-24-sick-from-multi-state-listeria-outbreak-linked-to-soft-cheeses/
Backyard chickens linked to multi-state outbreaks of salmonella infections  Backyard chickens linked to multi-state outbreaks of salmonella infections
The CDC reported 372 people in 47 states had been infected with outbreak strains of salmonella between Jan. 4, 2017 and May 13, 2017.
http://www.wlwt.com/article/backyard-chickens-linked-to-multi-state-outbreaks-of-salmonella-infections/9968593
Multi-state Microbial Food Contamination Epidemics timeline | Timetoast timelines  Multi-state Microbial Food Contamination Epidemics timeline | Timetoast timelines
Timetoasts free timeline maker lets you create timelines online. Make educational timelines or create a timeline for your company website. How to make a timeline? Well, its easy as toast!
https://www.timetoast.com/timelines/1524
3rd German Pharm-Tox Summit: Abstract submission  3rd German Pharm-Tox Summit: Abstract submission
3|sup|rd|/sup| German Pharm-Tox Summit 3|sup|rd|/sup| German Pharm-Tox Summit - a joint meeting:|br /|84|sup|th|/sup| Annual Meeting of the |b|German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)|/b||br /|20|sup|th|/sup| Annual Meeting of |b|Association of Clinical Pharmacology (VKliPha)|/b||br /|With contribution of AGAH|br /|26 February-1 March 2018 • Göttingen
http://www.gpts-kongress.de/index.php?id=18246
Sterilization | AORN Facility Reference Center  Sterilization | AORN Facility Reference Center
The AORN Facility Reference Center is the online home of the evidence-based AORN Guidelines for Perioperative Practice and associated tools for OR teams.
https://aornguidelines.org/guidelines/content?sectionid=173737535&view=book
The constitution of India has put the onus of making laws with respect to the incorporation, regulation and winding up the co...  The constitution of India has put the onus of making laws with respect to the incorporation, regulation and winding up the 'co...
The incorporation, regulation and winding up of co-operative societies (other than those operating in more than one State) is a State subject and is governed by the State laws on co-operative societies. In the case of co-operatives with objects not confined to one State, their incorporation, regulation and winding up fall in the central domain and are governed by the Multi-State Co-operative Societies Act, 2002. ...
https://academy.gktoday.in/mcq/qid-117-0598
Advanced Cardiovascular Diagnostics  Advanced Cardiovascular Diagnostics
... was founded by Dr. Perry Frankel, Board Certified Cardiologist and Lipidologist and multi-state diagnostician. He is a recognized national speaker on various topics including hyperlipidemia and hypertension.. ​. Advanced Cardiovascular Diagnostics focuses on the prevention of significant debilitating events ultimately saving lives. Dr. Frankel has designed a strategically targeted methodology to identify individuals that are most at risk for a cardiac event. We provide on site cardiac testing to corporations and health events throughout the NY metropolitan area.. ​. We have saved many lives using our cutting edge technology. Let us use our resources to save your workers lives and significantly reduce your healthcare insurance costs. Most health insurance plans accepted.. ...
http://cardiovasculartesting.com
Ohio Health Officials Investigate Disease Outbreak Linked To Petland Puppies | WOSU Radio  Ohio Health Officials Investigate Disease Outbreak Linked To Petland Puppies | WOSU Radio
Health officials in Ohio are working with the CDC to investigate a viral, multi-state outbreak traced to the Ohio-based Petland store chain.
https://radio.wosu.org/post/ohio-health-officials-investigate-disease-outbreak-linked-petland-puppies
IIAD tests system for response disease outbreak | Bovinevetonline  IIAD tests system for response disease outbreak | Bovinevetonline
For animal health officials, producers and veterinarians, a timely, coordinated and effective response to a multi-state animal health emergency is imperative to supporting the continuity of business that food animal ind
https://www.bovinevetonline.com/article/iiad-tests-system-response-disease-outbreak
Chronic Neutropenia (Symptoms, signs, causes, treatments & definition) - Medigest  Chronic Neutropenia (Symptoms, signs, causes, treatments & definition) - Medigest
Looking for information on Chronic Neutropenia? Medigest has all you need to know about Chronic Neutropenia - Symptoms and Signs, Causes, Treatments and definition
https://www.medigest.uk/diseases/chronic-neutropenia/
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell...  Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell...
TY - JOUR. T1 - Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. AU - Sauter, Craig S.. AU - Matasar, Matthew J.. AU - Meikle, Jessica. AU - Schoder, Heiko. AU - Ulaner, Gary A.. AU - Migliacci, Jocelyn C.. AU - Hilden, Patrick. AU - Devlin, Sean M.. AU - Zelenetz, Andrew D.. AU - Moskowitz, Craig. PY - 2015/4/16. Y1 - 2015/4/16. N2 - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients ...
https://miami.pure.elsevier.com/en/publications/prognostic-value-of-fdg-pet-prior-to-autologous-stem-cell-transpl
German Society for Racial Hygiene - Wikipedia  German Society for Racial Hygiene - Wikipedia
The German Society for Racial Hygiene (German: Deutsche Gesellschaft für Rassenhygiene) was a German eugenic organization founded on 22 June 1905 by the physician Alfred Ploetz in Berlin. Its goal was "for society to return to a healthy and blooming, strong and beautiful life" as Ploetz put it. The Nordic race was supposed to regain its "purity" through selective reproduction and sterilization. The society became defunct after World War II. Soon after the society was founded, it received generous support by the German imperial government and it was not the only organization of its kind in the world. Many organizations existed post WW2 with similar goals. Notable members comprised Ploetz brother-in-law Ernst Rüdin and his childhood friend Gerhart Hauptmann, Wilhelm Bölsche, Max von Gruber, Agnes Bluhm, Wilhelm Filchner, Anastasius Nordenholz, and Ludwig Hermann Plate. The biologists Ernst Haeckel and August Weismann, as well as the gynecologist Ernst Ludwig Alfred Hegar became honorary ...
https://en.wikipedia.org/wiki/German_Society_for_Racial_Hygiene
pancreatic cancer - Page 6 - Cancer Commons  pancreatic cancer - Page 6 - Cancer Commons
In a study reported in the Journal of Oncology Practice, Keng et al at Cleveland Clinic found that institution of an emergency department febrile neutropenia pathway for patients with cancer reduced the time to antibiotic administration compared with historical and direct admission cohorts.. "The study included all adult patients with cancer who presented with fever to the Cleveland Clinic Emergency Department between June 2012 and June 2013. The febrile neutropenia pathway interventions included providing patients with febrile neutropenia alert cards, standardizing the definition of febrile neutropenia and recognizing it as a distinct chief complaint, revising the emergency department triage level for febrile neutropenia, creating electronic febrile neutropenia order sets, administering empiric antibiotics before neutrophil count result, and relocating febrile neutropenia antibiotics to the emergency department. The primary outcome was time to antibiotic administration, with a target of 90 ...
https://www.cancercommons.org/tag/pancreatic-cancer/page/6/
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of...  The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of...
article{1195807, abstract = {Background: The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10\% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium. The existence of a medical need for G-CSF primary and secondary prophylaxis with these regimens was investigated in a real-life setting. Methods: Nine oncologists and six hematologists from different Belgian general hospitals and university centers were surveyed to collect expert opinion and real-life data (year 2007) on the use of chemotherapy regimens with moderate or high risk of febrile neutropenia and the clinical management of FN in patients aged {\textlangle}65 years with breast cancer or NHL. Data were retrospectively obtained, over a 6-month observation period. Results: The most frequently used regimens in breast cancer patients (n = 161) were FEC (45\%), FEC-T (37\%) and docetaxel alone (6\%). In ...
https://biblio.ugent.be/publication/1195807
Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile Neutropenia : Clinical...  Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile Neutropenia : Clinical...
The novel inflammatory marker procalcitonin (PCT) was assessed as an index of infection in patients with febrile neutropenia. Blood samples were obtained from 115 patients with febrile neutropenia for determination of PCT levels before onset of fever and daily until the resolution of fever. The median PCT level on the first day of fever was 8.23 ng/mL in patients with bacteremia, compared with 0.86 ng/mL in patients with localized bacterial infections (P = .017). The median PCT level on the first day of fever was 2.62 ng/mL in patients with severe sepsis, compared with 0.57 ng/mL in patients with clinically localized infections (P , .001). A dramatic decrease in PCT levels was documented after resolution of the infection; PCT levels were elevated when the infection worsened. Pronounced PCT levels were also found in patients with fever of unknown origin who were responding to antimicrobial chemotherapy, compared with those not responding to treatment with antibiotics. PCT levels were particularly ...
http://oxfordindex.oup.com/view/10.1086/320744
Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data |...  Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data |...
Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins Rde M, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS; Brighton Collaboration Viscerotropic Disease Working Group. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(33):5038-5058 ...
https://www.equator-network.org/reporting-guidelines/viscerotropic-disease-case-definition-and-guidelines-for-collection-analysis-and-presentation-of-immunization-safety-data/
RMK - Hämatologie, Onkologie und Palliativmedizin  RMK - Hämatologie, Onkologie und Palliativmedizin
Matzdorff A, Riess H, Bergmann F, Bisping G, Koschmieder S, Parmentier S, Petrides PE, Sosada M. Cancer Screening in Patients with Idiopathic Venous Thromboembolism--a Position Paper of the German Society of Hematology and Oncology Working Group on Hemostasis. Oncol Res Treat 2015;38(9):454-458. Staiger AM, Ott MM, Parmentier S, Rosenwald A, Ott G, Horn H, Griese EU. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. Br J Haematol 2015;171(1):145-148. Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M, Stölzel U. Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas. Oncology 2015;89(5):294-303. Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, ...
https://www.rems-murr-kliniken.de/medizin/winnenden/haematologie-onkologie-palliativ.html
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose...  Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose...
We show that the improved PFS with Rd is accompanied by an improvement in HRQoL, showing both statistically significant and clinically meaningful changes from baseline. Rd showed statistical superiority to MPT in Side Effects of Treatment, and no evidence of inferiority to MPT in any of the pre-selected HRQoL domains. This finding is of importance because it demonstrates that the improved PFS in this study does not come at a cost of increased symptoms or decreased HRQoL.. The FIRST study is the largest phase III trial conducted in transplant-ineligible elderly NDMM patients to date, and the first to evaluate HRQoL in NDMM patients receiving Rd. Primary efficacy results from this study indicated that continuous Rd administration significantly improved PFS and OS at the interim analysis compared with the MPT regimen,19 highlighting a double paradigm change in a setting in which alkylating agents and fixed-duration chemotherapy have long been considered treatment standards. Indeed, non-MP regimens ...
http://www.haematologica.org/content/100/6/826
ASCO Releases Guideline Updates for the Use of Colony-stimulating Factors - http://cyto.blogs.sapo.pt  ASCO Releases Guideline Updates for the Use of Colony-stimulating Factors - http://cyto.blogs.sapo.pt
The authors highlight the evidence that comorbid conditions increase the risk of febrile neutropenia in patients treated with chemotherapy.. RELATED: Consider Febrile Neutropenia Risk When Administering Standard Treatment in Prostate Cancer. Furthermore, when taking into account age and type of cancer, a patients comorbidities continue to be an important predictor for febrile neutropenia.. Finally, the authors note that granulocyte-CSFs are expensive and questions remain to be answered on cost effectiveness. However, it is emphasized that choice of agent should be guided by the clinical scenario, not cost.. Reference. ...
http://cyto.blogs.sapo.pt/asco-releases-guideline-updates-for-the-138837
Body-Mass-Index | Google Assistant  Body-Mass-Index | Google Assistant
With this skill you can calculate your body mass index. For the evaluation of your weight, height, age and gender are needed. The evaluation takes place according to the DGE (German Society for Nutrition eV) as well as by age groups. Attention! This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial your local emergency response phone number. Icon made by freepic from www.flaticon.com
https://assistant.google.com/services/a/uid/0000000da1bfea3d
Presentations - Center for International Health - LMU Munich  Presentations - Center for International Health - LMU Munich
Nicoli F, Finessi V, Montagnani A, Gallerani E, Sicurella M, Destro F, Sforza F, Marconi P, Caputo A, Gavioli R (2012): Study of the effects of the Tat protein of HIV-1 on memory cells and on the control of viral reactivation in in-vivo models of latent infection. Poster presentation at Joint Meeting of German Society for Tropical Medicine and International Health (DTG) and German Society for Parasitology (DGP), 15-16 March 2012, Heidelberg, Germany. Conference website ...
http://www.international-health.uni-muenchen.de/publications/presentations/index.html
A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B cell...  A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B cell...
Central nervous system dissemination is a relatively uncommon but almost always fatal complication in diffuse large B cell lymphoma patients. Optimal therapy for central nervous involvement in this malignancy has not been established. In this paper, we aimed to evaluate the therapeutic effect of E7123, a celecoxib derivative that inhibits focal adhesion signaling, in a novel xenograft model of diffuse large B cell lymphoma with central nervous system involvement. Cells obtained after disaggregation of HT subcutaneous tumors (HT-SC cells) were intravenously injected in NOD/SCID mice. These mice received oral vehicle or 75 mg/kg of E7123 daily until they were euthanized for weight loss or signs of sickness. The antitumor effect of E7123 was validated in an independent experiment using a bioluminescent mouse model. Intravenously injected HT-SC cells showed higher take rate and higher central nervous system tropism (associated with increased expression of β1-integrin and p130Cas proteins) than HT ...
http://www.haematologica.org/content/early/2013/05/03/haematol.2012.071811
AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
NeutropeniaFebrile NeutropeniaChemotherapy-Induced Febrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsFeverTaxoidsChemotherapy, AdjuvantDrug Administration ScheduleGranulocyte Colony-Stimulating FactorTreatment OutcomeCisplatinAntineoplastic AgentsPaclitaxelDoxorubicinNeoplasmsCyclophosphamideInfusions, IntravenousDeoxycytidineVinblastineDisease-Free SurvivalSurvival AnalysisCombined Modality TherapyAntineoplastic Agents, PhytogenicCamptothecinLung NeoplasmsCarboplatinAgranulocytosisBreast NeoplasmsMaximum Tolerated DoseSurvival RateEtoposideNeoplasm StagingFever of Unknown OriginOrganoplatinum CompoundsIfosfamideMycosesThrombocytopeniaHematologic DiseasesNeoadjuvant TherapyHematologic NeoplasmsDose-Response Relationship, DrugNeoplasm MetastasisLeukopeniaFluorouracilCarcinoma, Non-Small-Cell LungNauseaAnthracyclinesEpirubicinAntimetabolites, AntineoplasticBacterial InfectionsSalvage TherapyProspective StudiesNeoplasm Recurrence, LocalPrognosisLymphoma, Non-HodgkinAnti-Bacterial AgentsMethotrexateOpportunistic InfectionsDrug Resistance, NeoplasmMucositisAntibiotic ProphylaxisImmunocompromised HostVomitingOxonic AcidTegafurAdenocarcinomaPenicillanic AcidMitoxantroneLeucovorinTime FactorsAdministration, OralDisease ProgressionLeukocyte CountAntineoplastic Agents, AlkylatingOvarian NeoplasmsFollow-Up StudiesBleomycinPlatinum CompoundsDrug-Related Side Effects and Adverse ReactionsAntibiotics, AntineoplasticFeasibility StudiesBacteremiaKaplan-Meier EstimateTopotecanBridged CompoundsRecombinant ProteinsGuanineAlopeciaAntibodies, Monoclonal, HumanizedVincristineStomach NeoplasmsPiperacillinColorectal NeoplasmsAntifungal AgentsAmikacinStomatitisInfectionInduction ChemotherapyAntibodies, Monoclonal, Murine-DerivedRecurrenceGlutamatesTransplantation, AutologousUrologic NeoplasmsPeritoneal NeoplasmsRetrospective StudiesHematologyPrednisoneLeukemia, Myeloid, AcuteRandomized Controlled Trials as TopicClinical Trials as TopicBiosimilar PharmaceuticalsHematopoietic Stem Cell TransplantationAmbulatory CareCarcinoma, Small CellPrecursor Cell Lymphoblastic Leukemia-LymphomaComplement Hemolytic Activity AssayRisk FactorsArea Under CurveAntibodies, MonoclonalCancer Care FacilitiesThienamycinsCytarabineLymphomaSarcomaDrug Therapy, CombinationCarcinoma, Squamous CellRemission InductionGram-Negative Bacterial InfectionsAmphotericin BQuality of LifeTreatment FailurePrednisoloneAnemiaCarcinomaPilot ProjectsDacarbazineLength of StayLymphatic MetastasisCarcinoma, Transitional CellHead and Neck NeoplasmsRisk AssessmentNeutrophilsCephalosporinsDrug CombinationsColony-Stimulating FactorsGram-Positive Bacterial InfectionsDiarrheaCeftazidimeChemotherapy, Cancer, Regional PerfusionRadiotherapy, AdjuvantHodgkin DiseaseFelty SyndromeLeukocyte ElastaseArabinonucleosidesInjections, IntravenousFatigueMultivariate AnalysisBrain NeoplasmsRadiotherapyMelphalanBone MarrowDouble-Blind MethodTesticular NeoplasmsCarmustineInappropriate PrescribingMitomycinBone NeoplasmsLiver NeoplasmsReceptor, erbB-2Esophageal NeoplasmsGranulocyte-Macrophage Colony-Stimulating FactorBlood Cell CountLomustineAnti-Infective AgentsHealth Care CostsReceptors, Granulocyte Colony-Stimulating FactorHospitalizationInfusions, Intra-ArterialPredictive Value of TestsCohort StudiesPalliative CareDrug EvaluationRadiotherapy DosageCost-Benefit AnalysisNeoplasms, Germ Cell and EmbryonalThiotepaCalcitoninDrug TherapyDaunorubicinEchinocandinsTumor Markers, BiologicalMannose-Binding LectinJapanVindesineOsteosarcomaBone Marrow DiseasesAntiemeticsBone Marrow TransplantationAge FactorsPlatinumLeukemia, Myeloid

Image Gallery : Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy : Anti-Cancer...Image Gallery : Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy : Anti-Cancer...

Home , November 2015 - Volume 26 - Issue 10 , Chemotherapy-induced neutropenia and febrile neutropenia in... , Image Gallery ... Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy Anti-Cancer Drugs26(10):1054- ...
more infohttps://journals.lww.com/anti-cancerdrugs/Pages/imagegallery.aspx?year=2015&issue=11000&article=00006

Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies | European...Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies | European...

Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies. T Urban, B ... Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies ... Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies ... Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies ...
more infohttps://erj.ersjournals.com/content/13/6/1228

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases | BMC...Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases | BMC...

Healthcare claims databases have been used in several studies to characterize the risk and burden of chemotherapy-induced ... febrile neutropenia (FN) and effectiveness of colony-stimulating factors against FN. The accuracy of methods previously used to ... Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. ... databases have been used in several studies to characterize the risk and burden of chemotherapy-induced febrile neutropenia (FN ...
more infohttps://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-60

Chemotherapy-Induced Febrile NeutropeniaChemotherapy-Induced Febrile Neutropenia

... On-line free medical diagnosis assistant. Ranked list of possible diseases from ... "Chemotherapy-Induced Febrile Neutropenia"Drugs, active principles and "Chemotherapy-Induced Febrile Neutropenia"Medicinal ... Chemotherapy-Induced Febrile Neutropenia. fever accompanied by a significant reduction in NEUTROPHIL count associated with ...
more infohttps://lookfordiagnosis.com/mesh_info.php?term=Chemotherapy-Induced+Febrile+Neutropenia&lang=1

Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]

Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia. Joo Han Lim1, ... Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia. Turk J Hematol ... OBJECTIVE: Febrile neutropenia (FN) is a major toxic responseto chemotherapy requiring prompt medical attention. There are a ... Keywords: Neutropenia, fever, emergency department, chemotherapy. Joo Han Lim, Hoon Kim, Woong Gil Choi, Kyung Hwan Kim, Dong ...
more infohttp://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-27136

Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia [Turk J Hematol]

Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia. Joo Han Lim1, ... Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia. Turk J Hematol ... OBJECTIVE: Febrile neutropenia (FN) is a major toxic responseto chemotherapy requiring prompt medical attention. There are a ... Keywords: Neutropenia, fever, emergency department, chemotherapy. Joo Han Lim, Hoon Kim, Woong Gil Choi, Kyung Hwan Kim, Dong ...
more infohttp://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-27136&look4=

Advantages of pegfilgrastim over filgrastim in managing chemotherapy-induced febrile neutropenia - OncologyTubeAdvantages of pegfilgrastim over filgrastim in managing chemotherapy-induced febrile neutropenia - OncologyTube

... discusses research on the benefits of pegfilgrastim over filgrastim in managing chemotherapy-induced febrile neutropenia (FN), ... in addition to showing a reduction in febrile neutropenia compared to patients treated with filgrastim for 5 or 11 days). He ... Dr Aapro explains how a single injection of long-acting pegfilgrastim given 24 hours after chemotherapy is sufficient, ... com/videoEmbed/advantages-of-pegfilgrastim-over-filgrastim-in-managing-chemotherapy-induced-febrile-neutropenia frameborder=0 ...
more infohttps://www.oncologytube.com/video/advantages-of-pegfilgrastim-over-filgrastim-in-managing-chemotherapy-induced-febrile-neutropenia

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis...Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis...

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis ... and that such patients have a higher risk of febrile neutropenia hospitalization (FNH). Little is known about the number and ... Study population comprised adults who received a chemotherapy course with a high-risk regimen, or an intermediate-risk regimen ... CONCLUSIONS: In this retrospective evaluation, one-half of FNH episodes, outcomes, and costs among cancer chemotherapy patients ...
more infohttps://sharedresources.fredhutch.org/publications/papers/burden-chemotherapy-induced-febrile-neutropenia-hospitalizations-us-clinical

Corticosteroids, IV antibiotics increase risk for chemotherapy-induced febrile neutropenia - Healio - Global GenesCorticosteroids, IV antibiotics increase risk for chemotherapy-induced febrile neutropenia - Healio - Global Genes

Corticosteroids, IV antibiotics increase risk for chemotherapy-induced febrile neutropenia Healio. Use of corticosteroids, ... and antibiotics all appeared to increase risk for chemotherapy-induced febrile neutropenia … ...
more infohttps://globalgenes.org/news/corticosteroids-iv-antibiotics-increase-risk-for-chemotherapy-induced-febrile-neutropenia-healio/

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors<...Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors<...

Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ... Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ... Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ... Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ...
more infohttps://moh-it.pure.elsevier.com/en/publications/pegfilgrastim-for-the-prevention-of-chemotherapy-induced-febrile-

Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients / drcalapai.netFermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients / drcalapai.net

Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients * ... drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia ... of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia ... 30 febrile neutropenic episodes (24.8%) in the MSC group versus 46 (43.4%) in the control group (Wilcoxon signed rank test, P ...
more infohttp://drcalapai.net/articles/fermented-wheat-germ-extract-avemar-in-the-treatment-of-cancer-and-autoimmune-diseases-2

Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile...Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile...

401 experienced a total of 458 febrile neutropeniaepisodes. Risk of febrile neutropenia during the chemotherapy regimen course ... Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J ... Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J ... Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J ...
more infohttp://pai2.com/2014/04/12/weycker-d-barron-r-kartashov-legg-j-lyman-gh-incidence-treatment-consequences-chemotherapy-induced-febrile-neutropenia-inpatient-outpatient-settings-j-oncol-pharm-pract-201/

Institute of Cancer Research Repository - A prospective study of chemotherapy-induced febrile neutropenia in the South West...Institute of Cancer Research Repository - A prospective study of chemotherapy-induced febrile neutropenia in the South West...

BACKGROUND: Chemotherapy-induced febrile neutropenia is a medical emergency complicating the treatment of many cancer patients ... METHODS: A prospective study of all cases of chemotherapy-induced febrile neutropenia in the South West London Cancer Network ... A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of ... A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of ...
more infohttp://publications.icr.ac.uk/10407/

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated same-day (<...Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (<...

... are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Guidelines ... Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day ... RESULTS: A total of 5930 chemotherapy cycles from 1423 evaluable patients from MONITOR-GCSF had data for day of G-CSF ... Endotoxin-induced immunotolerance is associated with loss of monocyte metabolic plasticity and reduction of oxidative burst. ...
more infohttps://read.qxmd.com/read/30343410/outcomes-of-chemotherapy-induced-febrile-neutropenia-prophylaxis-with-biosimilar-filgrastim-zarzio%C3%A2-initiated-same-day-24-h-per-guidelines-24-72-h-and-late-72-h-findings-from-the-monitor-gcsf-study

Randomized Trial of Cefepime Monotherapy or Cefepime in Combination with Amikacin as Empirical Therapy for Febrile NeutropeniaRandomized Trial of Cefepime Monotherapy or Cefepime in Combination with Amikacin as Empirical Therapy for Febrile Neutropenia

Filgrastim in Patients with Chemotherapy-induced Febrile Neutropenia. Maher, Darryl W.; Liesehke, Graham J.; Green, Michael; ... Septic shock and chemotherapy-induced cytopenia: effects on microcirculation. Karvunidis, Thomas; Chvojka, Jiri; Lysak, Daniel ... Background: Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during ... Randomized Trial of Cefepime Monotherapy or Cefepime in Combination with Amikacin as Empirical Therapy for Febrile Neutropenia. ...
more infohttp://connection.ebscohost.com/c/articles/23179544/randomized-trial-cefepime-monotherapy-cefepime-combination-amikacin-as-empirical-therapy-febrile-neutropenia

Wheat Germ | GreenMedInfo | Substance | Natural MedicineWheat Germ | GreenMedInfo | Substance | Natural Medicine

Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric patients.Oct 01, 2004. ... Avemar and Echinacea extracts can effectively induce mobilization and homing of CD34+ stem cells to the myocardial tissue and ...
more infohttps://www.greenmedinfo.com/substance/wheat-germ

Symptom Management - The ASCO PostSymptom Management - The ASCO Post

Study Identifies Significant Risk Factors for Chemotherapy-Induced Febrile Neutropenia New research by Family et al in JNCCN- ... Journal of the National Comprehensive Cancer Network identifies risk factors for chemotherapy-induced febrile neutropenia, a ... Eric Roeland, MD, on Preventing Chemotherapy-Induced Vomiting Eric Roeland, MD, of Massachusetts General Hospital, discusses ... ESMO 2018: Pooled Analysis of Influence of Sex on Chemotherapy Efficacy and Toxicity in Esophagogastric Cancer. In an analysis ...
more infohttp://ascopost.com/topics/supportive-care/symptom-management/

Health information and publications in Africa African Index Medicus DatabaseHealth information and publications in Africa African Index Medicus Database

1 result(s) search for keyword(s) Chemotherapy-Induced Febrile Neutropenia Add the result to your basket Refine your search ... Actinomycosis, Cervicofacial Fasciitis, Necrotizing Chemotherapy-Induced Febrile Neutropenia Oral Hygiene Carcinoma Nigeria - ... Actinomycosis, Cervicofacial Fasciitis, Necrotizing Chemotherapy-Induced Febrile Neutropenia Oral Hygiene Carcinoma Nigeria - ... No oral assessment was carried out prior to commencement of chemotherapy to detect a potential source of infection. Management ...
more infohttp://indexmedicus.afro.who.int/aim/opac_css/index.php?lvl=more_results&mode=keyword&user_query=Chemotherapy-Induced+Febrile+Neutropenia&tags=ok

Neutropenia Archives - Oncology Nurse AdvisorNeutropenia Archives - Oncology Nurse Advisor

Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified By Tiffany Garbutt, PhD ... Pegteograstim may be effective for reducing chemotherapy-induced neutropenia Publish Date October 1, 2015 ... various cancers to identify clinical factors that contribute to the risk of developing chemotherapy-induced febrile neutropenia ... Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer. ...
more infohttps://www.oncologynurseadvisor.com/tag/neutropenia/

Browse | JNCCNBrowse | JNCCN

Introduction: Febrile neutropenia (FN) induced by chemotherapy (ChT) arises until 6 weeks after the last cycle, usually between ... BPI19-010: Febrile Neutropenia Induced by Chemotherapy: Impact of Risk Re-Stratification ... Profound neutropenia was observed in 43% and severe neutropenia in 36%. Overall mortality rate was 13%. Sepsis was diagnosed in ... Methods: Retrospective study of patients with diagnosis of FN induced by ChT, admitted to our center between 2012 and 2016. ...
more infohttps://jnccn.org/browse?f_0=author&page=9&pageSize=10&sort=datedescending

Hoffman EW[au] - PubMed - NCBIHoffman EW[au] - PubMed - NCBI

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. ... Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian ... Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses ... Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Hoffman+EW%5Bau%5D&dispmax=50

Al-Shehri A[au] - PubMed - NCBIAl-Shehri A[au] - PubMed - NCBI

Chemotherapy-induced febrile neutropenia in patients with breast cancer. A multivariate risk assessment model for first cycle ... The promising effect of linagliptin and/or indole-3-carbinol on experimentally-induced polycystic ovarian syndrome. ... Assessment of physicians knowledge and attitudes in the management of febrile seizures. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Al-Shehri+A%5Bau%5D&dispmax=50

2012 - Volume 10 - Issue 40 : JBI Evidence Synthesis2012 - Volume 10 - Issue 40 : JBI Evidence Synthesis

Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic ...
more infohttps://journals.lww.com/jbisrir/toc/2012/10400

Guidelines for Preventing Health-Care--Associated Pneumonia, 2003Guidelines for Preventing Health-Care--Associated Pneumonia, 2003

Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med ... Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin ... Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results ... most intensive chemotherapy (e.g., patients with childhood acute myelogenous leukemia). Abbreviations Used In the Guideline ...
more infohttps://www.cdc.gov/mmwr/preview/mmwrhtml/rr5303a1.htm

Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study | SpringerLinkRisk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study | SpringerLink

... for febrile neutropenia (FN) as prophylaxis in chemotherapy protocols with the r ... Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients ... Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J ... Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim ( ...
more infohttps://rd.springer.com/article/10.1007%2Fs00520-019-04879-x
AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
NeutropeniaFebrile NeutropeniaChemotherapy-Induced Febrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsFeverTaxoidsChemotherapy, AdjuvantDrug Administration ScheduleGranulocyte Colony-Stimulating FactorTreatment OutcomeCisplatinAntineoplastic AgentsPaclitaxelDoxorubicinNeoplasmsCyclophosphamideInfusions, IntravenousDeoxycytidineVinblastineDisease-Free SurvivalSurvival AnalysisCombined Modality TherapyAntineoplastic Agents, PhytogenicCamptothecinLung NeoplasmsCarboplatinAgranulocytosisBreast NeoplasmsMaximum Tolerated DoseSurvival RateEtoposideNeoplasm StagingFever of Unknown OriginOrganoplatinum CompoundsIfosfamideMycosesThrombocytopeniaHematologic DiseasesNeoadjuvant TherapyHematologic NeoplasmsDose-Response Relationship, DrugNeoplasm MetastasisLeukopeniaFluorouracilCarcinoma, Non-Small-Cell LungNauseaAnthracyclinesEpirubicinAntimetabolites, AntineoplasticBacterial InfectionsSalvage TherapyProspective StudiesNeoplasm Recurrence, LocalPrognosisLymphoma, Non-HodgkinAnti-Bacterial AgentsMethotrexateOpportunistic InfectionsDrug Resistance, NeoplasmMucositisAntibiotic ProphylaxisImmunocompromised HostVomitingOxonic AcidTegafurAdenocarcinomaPenicillanic AcidMitoxantroneLeucovorinTime FactorsAdministration, OralDisease ProgressionLeukocyte CountAntineoplastic Agents, AlkylatingOvarian NeoplasmsFollow-Up StudiesBleomycinPlatinum CompoundsDrug-Related Side Effects and Adverse ReactionsAntibiotics, AntineoplasticFeasibility StudiesBacteremiaKaplan-Meier EstimateTopotecanBridged CompoundsRecombinant ProteinsGuanineAlopeciaAntibodies, Monoclonal, HumanizedVincristineStomach NeoplasmsPiperacillinColorectal NeoplasmsAntifungal AgentsAmikacinStomatitisInfectionInduction ChemotherapyAntibodies, Monoclonal, Murine-DerivedRecurrenceGlutamatesTransplantation, AutologousUrologic NeoplasmsPeritoneal NeoplasmsRetrospective StudiesHematologyPrednisoneLeukemia, Myeloid, AcuteRandomized Controlled Trials as TopicClinical Trials as TopicBiosimilar PharmaceuticalsHematopoietic Stem Cell TransplantationAmbulatory CareCarcinoma, Small CellPrecursor Cell Lymphoblastic Leukemia-LymphomaComplement Hemolytic Activity AssayRisk FactorsArea Under CurveAntibodies, MonoclonalCancer Care FacilitiesThienamycinsCytarabineLymphomaSarcomaDrug Therapy, CombinationCarcinoma, Squamous CellRemission InductionGram-Negative Bacterial InfectionsAmphotericin BQuality of LifeTreatment FailurePrednisoloneAnemiaCarcinomaPilot ProjectsDacarbazineLength of StayLymphatic MetastasisCarcinoma, Transitional CellHead and Neck NeoplasmsRisk AssessmentNeutrophilsCephalosporinsDrug CombinationsColony-Stimulating FactorsGram-Positive Bacterial InfectionsDiarrheaCeftazidimeChemotherapy, Cancer, Regional PerfusionRadiotherapy, AdjuvantHodgkin DiseaseFelty SyndromeLeukocyte ElastaseArabinonucleosidesInjections, IntravenousFatigueMultivariate AnalysisBrain NeoplasmsRadiotherapyMelphalanBone MarrowDouble-Blind MethodTesticular NeoplasmsCarmustineInappropriate PrescribingMitomycinBone NeoplasmsLiver NeoplasmsReceptor, erbB-2Esophageal NeoplasmsGranulocyte-Macrophage Colony-Stimulating FactorBlood Cell CountLomustineAnti-Infective AgentsHealth Care CostsReceptors, Granulocyte Colony-Stimulating FactorHospitalizationInfusions, Intra-ArterialPredictive Value of TestsCohort StudiesPalliative CareDrug EvaluationRadiotherapy DosageCost-Benefit AnalysisNeoplasms, Germ Cell and EmbryonalThiotepaCalcitoninDrug TherapyDaunorubicinEchinocandinsTumor Markers, BiologicalMannose-Binding LectinJapanVindesineOsteosarcomaBone Marrow DiseasesAntiemeticsBone Marrow TransplantationAge FactorsPlatinumLeukemia, Myeloid
FilgrastimInfectionDuration of neutropeniaColony-stimulaProphylaxisPegfilgrastimHospitalizationNeutropenic episodesMyelosuppressive chemotherapyFeverEpisodesDiagnosisBurdenRiskAdultMortality rateEvaluable patientsHematologicTumorCancer PatientsRegimenConsequencesAlterationsToxicitySupportiveBreast cancerDetectOutcomesOBJECTIVECyclesManagementTreatmentStudyResultsResearchTotal

Filgrastim7

search

Infection9

search

Duration of neutropenia1

search

Colony-stimula2

search

Prophylaxis6

search

Pegfilgrastim4

search

Hospitalization2

search

Neutropenic episodes1

search

Myelosuppressive chemotherapy2

search

Fever3

search

Episodes4

search

Diagnosis1

search
  • Forty-one children (2 - 17 years old) with a diagnosis of intermediate or standard risk ALL who were treated with chemotherapy between April 2011 and June 2015 whose files were complete, were included in this study. (scirp.org)

Burden1

search

Risk6

search

Adult2

search
  • Research supports use of the Exergen professional TAT-5000 temporal thermometer as a noninvasive alternative to measure temperature in adult patients to detect febrile neutropenia, found research presented at the ONS 38th Annual Congress. (oncologynurseadvisor.com)
  • From December 2014 through August 2016, a total of 181 adult patients who were prescribed oral targeted therapy or chemotherapy enrolled in a randomized study of adherence and symptom management at Massachusetts General Hospital Cancer Center. (jnccn.org)

Mortality rate1

search

Evaluable patients1

search
  • A total of 5930 chemotherapy cycles from 1423 evaluable patients from MONITOR-GCSF had data for day of G-CSF initiation: 795 cycles (13.4%) classified as same-day, 3320 (56.0%) as per-guidelines, and 1815 (30.6%) as late. (qxmd.com)

Hematologic2

search

Tumor3

search
  • There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy. (tjh.com.tr)
  • One major conclusion that one can draw from these studies is that HAI therapy has resulted in higher tumor response rates than systemic chemotherapy. (guwsmedical.info)
  • Fajka-Boja R, Hidvegi M, Shoenfeld Y, Ion G, Demydenko D, Tomoskozi-Farkas R, Vizler Cs, Telekes A, Resetar A, Monostori E: Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines. (wikipedia.org)

Cancer Patients2

search

Regimen1

search

Consequences1

search

Alterations2

search
  • Purpose: Neutrophil and platelet activation and their interactions with endothelial cells are considered central features of sepsis-induced microcirculatory alterations. (ebscohost.com)
  • Fungal infections are more likely to develop after prolonged periods of neutropenia and antibiotic-induced alterations of alimentary canal and respiratory tract flora. (annals.org)

Toxicity1

search

Supportive2

search
  • This sets the stage for prospective, randomized phase III comparison between HAI therapy and systemic chemotherapy or best supportive care. (guwsmedical.info)
  • This success could be achieved by high-dose chemotherapy and supportive treatments. (scirp.org)

Breast cancer1

search

Detect1

search
  • Since most individual trials are small and therefore not adequately powered to detect a small difference in overall survival (OS), two meta-analyses have been performed in order to determine whether HAI therapy confers a survival benefit over systemic chemotherapy (Table 1) (39,40). (guwsmedical.info)

Outcomes1

search
  • RESULTS AND CONCLUSION: Our results reflect those of the recent National Chemotherapy Advisory Group (NCEPOD, 2008)/National Confidential Enquiry into Patient Outcomes and Death reports (NCAG, 2009) and highlight the need for network-wide c inical care pathways to improve outcomes in this area, British Journal of Cancer (2011) 104, 407-412. (icr.ac.uk)

OBJECTIVE1

search

Cycles2

search
  • each chemotherapy cycle within the course and each FNH episode within the cycles were identified. (fredhutch.org)
  • There were no significant differences in the average age of the patients, the length of treatment time (MSC) or follow-up, the number of patients with central venous catheters, the number of chemotherapy cycles, the frequency of preventive counterneutropenic interventions, or the type and dosage of antibiotic and antipyretic therapy used in the two groups. (drcalapai.net)

Management3

search

Treatment2

search

Study2

search

Results1

search
  • In a prognostic factor analysis of chemotherapy results in germ cell tumors, the International Germ Cell Cancer Collaborative Group (IGCCCG) reviewed 637 patients treated for advanced seminoma . (guwsmedical.info)

Research1

search
  • It has been proposed as a measure to predict neutropenia, though some research indicates that it is less effective than lymphopenia. (wikipedia.org)

Total1

search